0001463972--12-312026Q3Vuzix Corp11P3MP1YP2Y2440002440002440002440001640001640000.66672.390.00333352183352182.410.0033false0001463972vuzi:OemProductAndWaveguideSalesMember2026-01-012026-09-300001463972vuzi:ExtendedWarrantiesMember2026-01-012026-09-300001463972vuzi:ChiefExecutiveOfficerAndChiefFinancialOfficerMemberus-gaap:PerformanceSharesMember2026-09-302026-09-300001463972vuzi:NonExecutivesOfficersMemberus-gaap:PerformanceSharesMember2026-01-012026-09-300001463972vuzi:PointInTimeMember2026-07-012026-09-300001463972vuzi:OverTimeInputMethodMember2026-07-012026-09-300001463972vuzi:PointInTimeMember2026-01-012026-09-300001463972vuzi:OverTimeInputMethodMember2026-01-012026-09-300001463972vuzi:PointInTimeMember2025-07-012025-09-300001463972vuzi:OverTimeInputMethodMember2025-07-012025-09-300001463972vuzi:PointInTimeMember2025-01-012025-09-300001463972vuzi:OverTimeInputMethodMember2025-01-012025-09-300001463972vuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMember2026-07-012026-09-300001463972us-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMember2026-07-012026-09-300001463972vuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMember2026-01-012026-09-300001463972us-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMember2026-01-012026-09-300001463972us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001463972vuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMember2025-07-012025-09-300001463972us-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMember2025-07-012025-09-300001463972us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-12-310001463972vuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMember2025-01-012025-09-300001463972us-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMember2025-01-012025-09-300001463972vuzi:AtMarketAtmOfferingMember2026-08-3100014639722026-08-310001463972vuzi:AtMarketAtmOfferingMember2024-05-3100014639722024-05-310001463972vuzi:AtMarketAtmOfferingMember2026-08-012026-08-3100014639722026-08-012026-08-310001463972us-gaap:SeriesAPreferredStockMember2026-09-300001463972us-gaap:SeriesAPreferredStockMember2025-12-310001463972us-gaap:SeriesBPreferredStockMember2026-06-300001463972us-gaap:SeriesBPreferredStockMember2025-09-300001463972us-gaap:SeriesBPreferredStockMember2025-06-300001463972us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300001463972us-gaap:AdditionalPaidInCapitalMember2026-01-012026-09-300001463972us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001463972us-gaap:AdditionalPaidInCapitalMember2025-01-012025-09-300001463972us-gaap:AdditionalPaidInCapitalMembervuzi:AtMarketAtmOfferingMember2026-07-012026-09-300001463972us-gaap:AdditionalPaidInCapitalMembervuzi:AtMarketAtmOfferingMember2026-01-012026-09-300001463972us-gaap:AdditionalPaidInCapitalMembervuzi:AtMarketAtmOfferingMember2025-07-012025-09-300001463972us-gaap:AdditionalPaidInCapitalMembervuzi:AtMarketAtmOfferingMember2025-01-012025-09-300001463972us-gaap:CommonStockMember2026-07-012026-09-300001463972us-gaap:CommonStockMember2026-01-012026-09-300001463972us-gaap:CommonStockMember2025-07-012025-09-300001463972us-gaap:CommonStockMember2025-01-012025-09-300001463972us-gaap:CommonStockMembervuzi:AtMarketAtmOfferingMember2026-07-012026-09-300001463972us-gaap:CommonStockMembervuzi:AtMarketAtmOfferingMember2026-01-012026-09-300001463972us-gaap:CommonStockMembervuzi:AtMarketAtmOfferingMember2025-07-012025-09-300001463972us-gaap:CommonStockMembervuzi:AtMarketAtmOfferingMember2025-01-012025-09-300001463972us-gaap:TreasuryStockCommonMember2026-09-300001463972us-gaap:RetainedEarningsMember2026-09-300001463972us-gaap:AdditionalPaidInCapitalMember2026-09-300001463972us-gaap:TreasuryStockCommonMember2026-06-300001463972us-gaap:RetainedEarningsMember2026-06-300001463972us-gaap:AdditionalPaidInCapitalMember2026-06-3000014639722026-06-300001463972us-gaap:TreasuryStockCommonMember2025-12-310001463972us-gaap:RetainedEarningsMember2025-12-310001463972us-gaap:AdditionalPaidInCapitalMember2025-12-310001463972us-gaap:TreasuryStockCommonMember2025-09-300001463972us-gaap:RetainedEarningsMember2025-09-300001463972us-gaap:AdditionalPaidInCapitalMember2025-09-300001463972us-gaap:TreasuryStockCommonMember2025-06-300001463972us-gaap:RetainedEarningsMember2025-06-300001463972us-gaap:AdditionalPaidInCapitalMember2025-06-3000014639722025-06-300001463972us-gaap:TreasuryStockCommonMember2024-12-310001463972us-gaap:RetainedEarningsMember2024-12-310001463972us-gaap:AdditionalPaidInCapitalMember2024-12-310001463972us-gaap:CommonStockMember2026-09-300001463972us-gaap:CommonStockMember2026-06-300001463972us-gaap:CommonStockMember2025-12-310001463972us-gaap:CommonStockMember2025-09-300001463972us-gaap:CommonStockMember2025-06-300001463972us-gaap:CommonStockMember2024-12-310001463972us-gaap:EmployeeStockOptionMember2025-01-012025-12-310001463972us-gaap:EmployeeStockOptionMember2026-09-300001463972us-gaap:EmployeeStockOptionMember2025-12-310001463972us-gaap:EmployeeStockOptionMember2026-01-012026-09-300001463972vuzi:IndependentBoardMembersMemberus-gaap:RestrictedStockUnitsRSUMember2026-09-300001463972vuzi:ChiefExecutiveOfficerAndChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2026-04-290001463972vuzi:ChiefExecutiveOfficerAndChiefFinancialOfficerMemberus-gaap:PerformanceSharesMember2026-04-290001463972vuzi:NonExecutivesOfficersMemberus-gaap:RestrictedStockUnitsRSUMember2026-04-240001463972vuzi:NonExecutivesOfficersMemberus-gaap:PerformanceSharesMember2026-04-240001463972vuzi:RestrictedStockAwardsAndStockUnitsMember2026-09-300001463972us-gaap:PerformanceSharesMember2026-09-300001463972vuzi:RestrictedStockAwardsAndStockUnitsMember2025-12-310001463972us-gaap:PerformanceSharesMember2025-12-310001463972srt:ChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2026-04-292026-04-290001463972srt:ChiefFinancialOfficerMemberus-gaap:PerformanceSharesMember2026-04-292026-04-290001463972srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2026-04-292026-04-290001463972srt:ChiefExecutiveOfficerMemberus-gaap:PerformanceSharesMember2026-04-292026-04-290001463972vuzi:NonExecutivesOfficersMemberus-gaap:PerformanceSharesMember2026-04-242026-04-240001463972vuzi:IndependentBoardMembersMemberus-gaap:RestrictedStockUnitsRSUMember2026-01-012026-09-300001463972vuzi:RestrictedStockAwardsAndStockUnitsMember2026-01-012026-09-300001463972us-gaap:PerformanceSharesMember2026-01-012026-09-300001463972vuzi:ChiefExecutiveOfficerAndChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2026-04-292026-04-290001463972vuzi:NonExecutivesOfficersMemberus-gaap:RestrictedStockUnitsRSUMember2026-04-242026-04-240001463972us-gaap:EmployeeStockOptionMembervuzi:LongTermIncentivePlanMember2025-01-012025-09-300001463972vuzi:PatentsAndTrademarkMember2026-01-012026-09-300001463972vuzi:LicensesMember2026-01-012026-09-300001463972vuzi:SmartGlassesAndIWearVideoHeadphonesSalesMember2026-07-012026-09-300001463972vuzi:EngineeringServicesMember2026-07-012026-09-300001463972vuzi:SmartGlassesAndIWearVideoHeadphonesSalesMember2026-01-012026-09-300001463972vuzi:EngineeringServicesMember2026-01-012026-09-300001463972vuzi:SmartGlassesAndIWearVideoHeadphonesSalesMember2025-07-012025-09-300001463972vuzi:EngineeringServicesMember2025-07-012025-09-300001463972vuzi:SmartGlassesAndIWearVideoHeadphonesSalesMember2025-01-012025-09-300001463972vuzi:EngineeringServicesMember2025-01-012025-09-3000014639722028-01-012026-09-3000014639722027-01-012026-09-3000014639722026-10-012026-09-300001463972vuzi:ExtendedWarrantiesMember2026-09-300001463972vuzi:ExtendedWarrantiesMember2025-12-310001463972vuzi:ToolingAndManufacturingEquipmentMember2026-09-300001463972vuzi:FurnitureAndEquipmentMember2026-09-300001463972us-gaap:LeaseholdImprovementsMember2026-09-300001463972us-gaap:ComputerEquipmentMember2026-09-300001463972vuzi:ToolingAndManufacturingEquipmentMember2025-12-310001463972vuzi:FurnitureAndEquipmentMember2025-12-310001463972us-gaap:LeaseholdImprovementsMember2025-12-310001463972us-gaap:ComputerEquipmentMember2025-12-310001463972vuzi:AtMarketAtmOfferingMember2024-05-012026-09-300001463972us-gaap:SubsequentEventMembervuzi:AtMarketAtmOfferingMember2026-10-012026-12-310001463972vuzi:AtMarketAtmOfferingMember2026-07-012026-09-300001463972vuzi:AtMarketAtmOfferingMember2026-01-012026-09-300001463972vuzi:AtMarketAtmOfferingMember2025-07-012025-09-300001463972vuzi:AtMarketAtmOfferingMember2025-01-012025-09-300001463972us-gaap:SeriesBPreferredStockMember2026-07-012026-09-300001463972us-gaap:SeriesBPreferredStockMember2026-01-012026-09-300001463972us-gaap:SeriesBPreferredStockMember2025-07-012025-09-300001463972us-gaap:SeriesBPreferredStockMember2025-01-012025-09-300001463972us-gaap:RetainedEarningsMember2025-07-012025-09-300001463972us-gaap:RetainedEarningsMember2025-01-012025-09-3000014639722025-01-012025-12-3100014639722024-01-012024-12-310001463972vuzi:PatentsAndTrademarksMember2026-09-300001463972us-gaap:LicensingAgreementsMember2026-09-300001463972vuzi:PatentsAndTrademarksMember2025-12-310001463972us-gaap:LicensingAgreementsMember2025-12-310001463972us-gaap:RetainedEarningsMember2026-07-012026-09-300001463972us-gaap:RetainedEarningsMember2026-01-012026-09-300001463972us-gaap:SeriesBPreferredStockMember2025-12-3100014639722025-07-012025-09-300001463972vuzi:EngineeringServicesMember2026-07-012026-09-300001463972us-gaap:ProductMember2026-07-012026-09-300001463972vuzi:EngineeringServicesMember2026-01-012026-09-300001463972us-gaap:ProductMember2026-01-012026-09-300001463972vuzi:EngineeringServicesMember2025-07-012025-09-300001463972us-gaap:ProductMember2025-07-012025-09-300001463972vuzi:EngineeringServicesMember2025-01-012025-09-300001463972us-gaap:ProductMember2025-01-012025-09-300001463972us-gaap:SeriesBPreferredStockMembervuzi:TrancheTwoMember2026-09-300001463972us-gaap:SeriesBPreferredStockMembervuzi:TrancheThreeMember2026-09-300001463972us-gaap:SeriesBPreferredStockMembervuzi:SecurityPurchaseAgreementWithQuantaComputerInc.Member2026-09-300001463972us-gaap:SeriesBPreferredStockMember2026-09-300001463972vuzi:CustomerTwoMembervuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-07-012026-09-300001463972vuzi:CustomerTwoMemberus-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-07-012026-09-300001463972vuzi:CustomerOneMembervuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-07-012026-09-300001463972vuzi:CustomerOneMemberus-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-07-012026-09-300001463972vuzi:OtherCountriesMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2026-07-012026-09-300001463972country:USus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2026-07-012026-09-300001463972country:DEus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2026-07-012026-09-300001463972country:CAus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2026-07-012026-09-300001463972us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2026-07-012026-09-300001463972vuzi:CustomerTwoMembervuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001463972vuzi:CustomerTwoMemberus-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001463972vuzi:CustomerOneMembervuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001463972vuzi:CustomerOneMemberus-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001463972vuzi:OtherCountriesMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2026-01-012026-09-300001463972vuzi:CustomerTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001463972vuzi:CustomerThreeMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001463972vuzi:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001463972country:USus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2026-01-012026-09-300001463972country:JPus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2026-01-012026-09-300001463972country:CHus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2026-01-012026-09-300001463972us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2026-01-012026-09-300001463972vuzi:CustomerTwoMembervuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300001463972vuzi:CustomerTwoMemberus-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300001463972vuzi:CustomerThreeMembervuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300001463972vuzi:CustomerThreeMemberus-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300001463972vuzi:CustomerOneMembervuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300001463972vuzi:CustomerOneMemberus-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300001463972vuzi:CustomerFourMembervuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300001463972vuzi:CustomerFourMemberus-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300001463972vuzi:OtherCountriesMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2025-07-012025-09-300001463972country:USus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2025-07-012025-09-300001463972country:JPus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2025-07-012025-09-300001463972country:CHus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2025-07-012025-09-300001463972us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2025-07-012025-09-300001463972vuzi:CustomerTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-12-310001463972vuzi:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-12-310001463972vuzi:CustomerTwoMembervuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300001463972vuzi:CustomerThreeMembervuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300001463972vuzi:CustomerOneMembervuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300001463972vuzi:CustomerOneMemberus-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300001463972vuzi:CustomerFourMembervuzi:EngineeringServicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300001463972vuzi:OtherCountriesMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2025-01-012025-09-300001463972country:USus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2025-01-012025-09-300001463972country:NLus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2025-01-012025-09-300001463972country:HUus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2025-01-012025-09-300001463972us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2025-01-012025-09-3000014639722025-09-3000014639722024-12-3100014639722025-01-012025-09-300001463972us-gaap:LicensingAgreementsMember2026-07-012026-09-300001463972us-gaap:LicensingAgreementsMember2026-01-012026-09-300001463972us-gaap:LicensingAgreementsMember2025-07-012025-09-300001463972us-gaap:LicensingAgreementsMember2025-01-012025-09-300001463972vuzi:SingleReportableSegmentMember2026-07-012026-09-300001463972vuzi:SingleReportableSegmentMember2026-01-012026-09-300001463972vuzi:SingleReportableSegmentMember2025-07-012025-09-300001463972vuzi:SingleReportableSegmentMember2025-01-012025-09-300001463972vuzi:PatentsAndTrademarksMember2026-07-012026-09-300001463972vuzi:PatentsAndTrademarksMember2026-01-012026-09-300001463972vuzi:PatentsAndTrademarksMember2025-07-012025-09-300001463972vuzi:PatentsAndTrademarksMember2025-01-012025-09-3000014639722026-09-3000014639722025-12-3100014639722026-07-012026-09-3000014639722026-11-1200014639722026-01-012026-09-30xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purevuzi:segmentvuzi:itemvuzi:productvuzi:customer

Table of Contents

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the Quarterly Period Ended September 30, 2026

OR

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

Commission file number 001-35955

VUZIX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

  ​ ​ ​

04-3392453

State or other jurisdiction of
incorporation or organization

(I.R.S. Employer
Identification No.)

​

25 Hendrix Road, Suite A
West Henrietta, New York

  ​ ​ ​

14586

(Address of principal executive offices)

(Zip Code)

​

Registrant’s telephone number, including area code: (585) 359-5900

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class:

  ​ ​ ​

Trading Symbol(s)

  ​ ​ ​

Name of each exchange on which registered:

Common Stock, par value $0.001

 

VUZI

 

Nasdaq Capital Market

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days.   Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

 

 

 

 

 

 

Smaller reporting company

☒

Emerging growth company

☐

 

 

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 12, 2026, there were 85,156,876 shares of the registrant’s common stock outstanding.

​

​

​

​

Table of Contents

Vuzix Corporation

INDEX

​

 

Page
No.

 

 

Part I – Financial Information

3

 

 

​

Item 1.

Consolidated Financial Statements (Unaudited):

3

 

​

Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025

3

 

​

​

Consolidated Statements of Changes in Mezzanine Equity and Stockholders’ Equity for the Three and Nine Months Ended September 30, 2026 and 2025

4

 

​

Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025

5

 

​

Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025

6

 

​

Notes to the Unaudited Consolidated Financial Statements

7

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

20

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

32

 

Item 4.

Controls and Procedures

32

 

Part II – Other Information

33

 

Item 1.

Legal Proceedings

33

 

Item 1A.

Risk Factors

33

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

33

 

Item 3.

Defaults Upon Senior Securities

33

 

Item 4.

Mine Safety Disclosure

33

 

Item 5.

Other Information

33

 

Item 6.

Exhibits

34

 

 

Signatures

​

35

​

​

​

2

Table of Contents

Part 1: FINANCIAL INFORMATION

Item 1: Consolidated Financial Statements

VUZIX CORPORATION

CONSOLIDATED BALANCE SHEETS

​

​

​

​

​

​

​

​

​

​

(Unaudited)

  ​ ​ ​

​

​

​

​

September 30, 

​

December 31,

​

  ​ ​ ​

2026

  ​ ​ ​

2025

ASSETS

 

​

  ​

 

​

  ​

Current Assets

 

​

  ​

 

​

  ​

Cash and Cash Equivalents

​

$

9,192,134

​

$

21,150,213

Accounts Receivable, net of allowance for credit losses of $14,388 at September 30, 2026 and $46,000 at December 31, 2025

​

 

596,951

​

 

1,627,635

Accrued Revenues in Excess of Billings

​

 

539,505

​

 

533,665

Other Receivables

​

​

454,103

​

​

379,615

Inventories, Net

​

 

2,229,615

​

 

2,188,750

Manufacturing Vendor Prepayments

​

 

252,512

​

 

256,090

Prepaid Expenses and Other Assets

​

 

1,407,944

​

 

1,059,759

​

​

​

​

​

​

​

Total Current Assets

​

 

14,672,764

​

 

27,195,727

​

​

​

​

​

​

​

Long-Term Assets

​

 

  ​

​

 

  ​

Fixed Assets, Net

​

 

9,122,721

​

 

7,626,238

Operating Lease Right-of-Use Assets, Net

​

​

610,481

​

​

1,003,025

Patents and Trademarks, Net

​

 

3,665,948

​

 

3,359,066

Technology Licenses, Net

​

 

409,170

​

 

559,973

Other Assets, Net

​

 

300,000

​

 

327,778

​

​

​

​

​

​

​

Total Assets

​

$

28,781,084

​

$

40,071,807

​

​

​

​

​

​

​

LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS' EQUITY

​

 

​

​

 

  ​

Current Liabilities

​

 

  ​

​

 

  ​

Accounts Payable

​

$

1,995,783

​

$

685,010

Unearned Revenue

​

 

6,424

​

 

62,361

Accrued Expenses

​

 

1,916,126

​

 

3,590,407

Other Taxes Payable

​

 

83,059

​

 

49,513

Operating Lease Right-of-Use Liabilities

​

​

500,911

​

​

500,911

​

​

​

​

​

​

​

Total Current Liabilities

​

 

4,502,303

​

 

4,888,202

​

​

​

​

​

​

​

Long-Term Liabilities

​

​

​

​

​

​

Operating Lease Right-of-Use Liabilities

​

​

109,570

​

​

502,114

​

​

​

​

​

​

​

Total Liabilities

​

 

4,611,873

​

 

5,390,316

​

​

​

​

​

​

​

Mezzanine Equity

​

 

  ​

​

 

  ​

Preferred Stock - $0.001 Par Value, 5,000,000 Shares Authorized; 419,959 Shares of Series B Preferred Stock Issued and Outstanding as of September 30, 2026 and December 31, 2025

​

 

10,000,000

​

 

10,000,000

​

​

​

​

​

​

​

Stockholders' Equity

​

 

  ​

​

 

  ​

Common Stock - $0.001 Par Value, 200,000,000 shares authorized; 85,227,031 shares issued and 84,647,359 shares outstanding as of September 30, 2026 and 81,679,367 shares issued and 81,099,695 shares outstanding as of December 31, 2025

​

 

85,227

​

 

81,680

Additional Paid-in Capital

​

 

439,617,602

​

 

426,934,722

Accumulated Deficit

​

 

(423,057,117)

​

 

(399,858,410)

Treasury Stock, at cost, 579,672 shares as of September 30, 2026 and December 31, 2025

​

 

(2,476,501)

​

 

(2,476,501)

​

​

​

​

​

​

​

Total Stockholders' Equity

​

 

14,169,211

​

 

24,681,491

​

​

​

​

​

​

​

Total Liabilities, Mezzanine Equity, and Stockholders' Equity

​

$

28,781,084

​

$

40,071,807

​

The accompanying notes are an integral part of these consolidated financial statements.

​

​

​

3

Table of Contents

VUZIX CORPORATION

CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY

(Unaudited)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Mezzanine Equity

​

Stockholders' Equity

​

​

Series B Preferred Stock

​

Common Stock

​

Additional

​

Accumulated

​

Treasury Stock

​

​

​

​

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Paid-In Capital

  ​ ​ ​

Deficit

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Total

Balance - July 1, 2026

​

419,959

​

$

10,000,000

 

84,993,902

​

$

84,994

​

$

438,138,532

​

$

(414,633,429)

​

(579,672)

​

$

(2,476,501)

​

$

21,113,596

Stock-Based Compensation Expense

 

—

​

 

—

 

—

​

 

—

​

 

881,465

​

 

—

 

—

​

 

—

​

 

881,465

Stock Option Exercises

 

—

​

 

—

 

14,501

​

 

14

​

 

(14)

​

 

—

 

—

​

 

—

​

 

—

Preferred Stock Dividends

 

—

​

 

—

 

—

​

 

—

​

 

—

​

 

(37,500)

 

—

​

 

—

​

 

(37,500)

Proceeds from ATM Program, Net

 

—

​

 

—

 

218,628

​

 

219

​

 

597,619

​

 

—

 

—

​

 

—

​

 

597,838

Net Loss

 

—

​

 

—

 

—

​

 

—

​

 

—

​

 

(8,386,188)

 

—

​

 

—

​

 

(8,386,188)

Balance - September 30, 2026

 

419,959

​

$

10,000,000

 

85,227,031

​

$

85,227

​

$

439,617,602

​

$

(423,057,117)

 

(579,672)

​

$

(2,476,501)

​

$

14,169,211

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Mezzanine Equity

​

Stockholders' Equity

​

​

Series B Preferred Stock

​

Common Stock

​

Additional

​

Accumulated

​

Treasury Stock

​

​

​

​

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Paid-In Capital

  ​ ​ ​

Deficit

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Total

Balance - January 1, 2026

​

419,959

​

$

10,000,000

 

81,679,367

​

$

81,680

​

$

426,934,722

​

$

(399,858,410)

​

(579,672)

​

$

(2,476,501)

​

$

24,681,491

Stock-Based Compensation Expense

 

—

​

 

—

 

135,447

​

 

135

​

 

2,174,244

​

 

—

 

—

​

 

—

​

 

2,174,379

Stock Option Exercises

 

—

​

 

—

 

193,589

​

 

194

​

 

(194)

​

 

—

 

—

​

 

—

​

 

—

Preferred Stock Dividends

 

—

​

 

—

 

—

​

 

—

​

 

—

​

 

(112,500)

 

—

​

 

—

​

 

(112,500)

Proceeds from ATM Program, Net

 

—

​

 

—

 

3,218,628

​

 

3,218

​

 

10,508,830

​

 

—

 

—

​

 

—

​

 

10,512,048

Net Loss

 

—

​

 

—

 

—

​

 

—

​

 

—

​

 

(23,086,207)

 

—

​

 

—

​

 

(23,086,207)

Balance - September 30, 2026

 

419,959

​

$

10,000,000

 

85,227,031

​

$

85,227

​

$

439,617,602

​

$

(423,057,117)

 

(579,672)

​

$

(2,476,501)

​

$

14,169,211

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Mezzanine Equity

​

Stockholders' Equity

​

​

Series B Preferred Stock

​

Common Stock

​

Additional

​

Accumulated

​

Treasury Stock

​

​

​

​

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Paid-In Capital

  ​ ​ ​

Deficit

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Total

Balance - July 1, 2025

​

189,717

​

$

5,000,000

 

77,921,364

​

$

77,921

​

$

415,089,886

​

$

(383,826,831)

​

(579,672)

​

$

(2,476,501)

​

$

28,864,475

Stock-Based Compensation Expense

 

—

​

 

—

 

121,055

​

 

122

​

 

769,638

​

 

—

 

—

​

 

—

​

 

769,760

Stock Option Exercises

 

—

​

 

—

 

41,250

​

 

41

​

 

54,821

​

 

—

 

—

​

 

—

​

 

54,863

Proceeds from ATM Program, Net

 

—

​

 

—

 

1,903,120

​

 

1,903

​

 

5,548,696

​

 

—

 

—

​

 

—

​

 

5,550,599

Stock Issued under Quanta Securities Purchase Agreement

 

230,242

​

 

5,000,000

​

—

​

 

—

​

 

—

​

 

—

 

—

​

 

—

​

 

—

Net Loss

 

—

​

 

—

​

—

​

 

—

​

 

—

​

 

(7,354,225)

 

—

​

 

—

​

 

(7,354,225)

Balance - September 30, 2025

 

419,959

​

$

10,000,000

 

79,986,789

​

$

79,987

​

$

421,463,041

​

$

(391,181,056)

 

(579,672)

​

$

(2,476,501)

​

$

27,885,471

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Mezzanine Equity

​

Stockholders' Equity

​

​

Series B Preferred Stock

​

Common Stock

​

Additional

​

Accumulated

​

Treasury Stock

​

​

​

​

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Paid-In Capital

  ​ ​ ​

Deficit

  ​ ​ ​

Shares

  ​ ​ ​

Amount

  ​ ​ ​

Total

Balance - January 1, 2025

​

—

​

$

—

 

76,553,694

​

$

76,553

​

$

407,215,883

​

$

(367,522,950)

​

(579,672)

​

$

(2,476,501)

​

$

37,292,985

Stock-Based Compensation Expense

​

—

​

​

—

​

121,055

​

​

122

​

​

4,503,178

​

​

—

​

—

​

​

—

​

​

4,503,300

Stock Option Exercises

 

—

​

 

—

 

105,185

​

 

105

​

 

106,738

​

 

—

 

—

​

 

—

​

 

106,843

Proceeds from ATM Program, Net

 

—

​

 

—

 

3,206,855

​

 

3,206

​

​

9,637,242

​

 

—

 

—

​

 

—

​

 

9,640,449

Stock Issued under Quanta Securities Purchase Agreement

 

419,959

​

 

10,000,000

 

—

​

 

—

​

 

—

​

 

—

 

—

​

 

—

​

 

—

Net Loss

 

—

​

 

—

 

—

​

 

—

​

 

—

​

 

(23,658,106)

 

—

​

 

—

​

 

(23,658,106)

Balance - September 30, 2025

 

419,959

​

$

10,000,000

 

79,986,789

​

$

79,987

​

$

421,463,041

​

$

(391,181,056)

 

(579,672)

​

$

(2,476,501)

​

$

27,885,471

The accompanying notes are an integral part of these consolidated financial statements.

​

​

​

4

Table of Contents

VUZIX CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30, 

​

Nine Months Ended September 30, 

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Sales:

 

​

  ​

 

​

  ​

 

​

  ​

 

​

  ​

Sales of Products

​

$

494,141

​

$

896,274

​

$

2,420,816

​

$

3,265,657

Sales of Engineering Services

​

 

220,308

​

 

264,673

​

 

798,447

​

 

771,941

​

​

​

​

​

​

​

​

​

​

​

​

​

Total Sales

​

 

714,449

​

 

1,160,947

​

 

3,219,263

​

 

4,037,598

​

​

​

​

​

​

​

​

​

​

​

​

​

Cost of Sales:

​

 

  ​

​

 

  ​

​

 

  ​

​

 

  ​

Cost of Sales - Products Sold

​

 

1,236,356

​

 

1,240,310

​

 

4,196,985

​

 

4,468,385

Cost of Sales - Depreciation and Amortization

​

​

84,063

​

​

180,927

​

​

240,383

​

​

525,144

Cost of Sales - Engineering Services

​

 

261,607

​

 

151,017

​

 

672,803

​

 

481,861

​

​

​

​

​

​

​

​

​

​

​

​

​

Total Cost of Sales

​

 

1,582,026

​

 

1,572,254

​

 

5,110,171

​

 

5,475,390

​

​

​

​

​

​

​

​

​

​

​

​

​

Gross Loss

​

 

(867,577)

​

 

(411,307)

​

 

(1,890,908)

​

 

(1,437,792)

​

​

​

​

​

​

​

​

​

​

​

​

​

Operating Expenses:

​

 

  ​

​

 

  ​

​

 

  ​

​

 

  ​

Research and Development

​

 

3,317,509

​

 

2,935,971

​

 

9,443,739

​

 

8,112,684

Selling and Marketing

​

 

1,640,931

​

 

1,147,194

​

 

4,401,741

​

 

4,037,649

General and Administrative

​

 

2,487,899

​

 

2,575,087

​

 

7,304,170

​

 

9,292,659

Depreciation and Amortization

​

 

163,458

​

 

424,335

​

 

396,719

​

 

1,242,828

​

​

​

​

​

​

​

​

​

​

​

​

​

Total Operating Expenses

​

 

7,609,797

​

 

7,082,587

​

 

21,546,369

​

 

22,685,820

​

​

​

​

​

​

​

​

​

​

​

​

​

Loss From Operations

​

 

(8,477,374)

​

 

(7,493,894)

​

 

(23,437,277)

​

 

(24,123,612)

​

​

​

​

​

​

​

​

​

​

​

​

​

Other Income (Expense):

​

 

  ​

​

 

  ​

​

 

  ​

​

 

​

Investment Income

​

 

108,029

​

 

156,760

​

 

434,196

​

 

460,998

Other Taxes

​

 

(14,000)

​

 

—

​

 

(50,458)

​

 

22,372

Foreign Exchange Gain (Loss)

​

 

(2,843)

​

 

(17,091)

​

 

(32,668)

​

 

(17,864)

​

​

​

​

​

​

​

​

​

​

​

​

​

Total Other Income, Net

​

 

91,186

​

 

139,669

​

 

351,070

​

 

465,506

​

​

​

​

​

​

​

​

​

​

​

​

​

Loss Before Provision for Income Taxes

​

 

(8,386,188)

​

 

(7,354,225)

​

 

(23,086,207)

​

 

(23,658,106)

Provision for Income Taxes

​

 

—

​

 

—

​

 

—

​

 

—

​

​

​

​

​

​

​

​

​

​

​

​

​

Net Loss

​

 

(8,386,188)

​

 

(7,354,225)

​

 

(23,086,207)

​

 

(23,658,106)

Preferred Stock Dividends

​

 

(37,500)

​

 

(21,177)

​

 

(112,500)

​

 

(24,670)

Loss Attributable to Common Shareholders

​

$

(8,423,688)

​

$

(7,375,402)

​

$

(23,198,707)

​

$

(23,682,776)

​

​

​

​

​

​

​

​

​

​

​

​

​

Basic and Diluted Net Loss per Common Share

​

$

(0.10)

​

$

(0.09)

​

$

(0.28)

​

$

(0.31)

Weighted-average Shares Outstanding - Basic and Diluted

​

 

84,415,649

​

 

77,478,532

​

 

83,354,246

​

 

76,733,716

​

The accompanying notes are an integral part of these consolidated financial statements.

​

5

Table of Contents

VUZIX CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

​

​

​

​

​

​

​

Cash Flows Used In Operating Activities

 

​

  ​

 

​

  ​

Net Loss

​

$

(23,086,207)

​

$

(23,658,106)

Non-Cash Adjustments

​

 

  ​

​

 

  ​

Depreciation and Amortization

​

 

1,526,379

​

 

2,342,483

Stock-Based Compensation

​

 

2,174,379

​

 

4,496,088

(Increase) Decrease in Operating Assets

​

 

  ​

​

 

​

Accounts Receivable

​

 

1,030,684

​

 

584,184

Accrued Revenues in Excess of Billings

​

 

(5,840)

​

 

243,409

Other Receivables

​

​

283,821

​

​

—

Inventories

​

 

(40,865)

​

 

1,917,817

Manufacturing Vendor Prepayments

​

 

3,578

​

 

216,268

Prepaid Expenses and Other Assets

​

 

(348,185)

​

 

(47,282)

Increase (Decrease) in Operating Liabilities

​

 

  ​

​

 

  ​

Accounts Payable

​

 

1,310,773

​

 

32,857

Accrued Expenses

​

 

(1,674,281)

​

 

618,672

Unearned Revenue

​

 

(55,937)

​

 

(25,116)

Other Taxes Payable

​

 

33,547

​

 

43,891

​

​

​

​

​

​

​

Net Cash Flows Used in Operating Activities

​

 

(18,848,154)

​

 

(13,234,835)

​

​

​

​

​

​

​

Cash Flows Used in Investing Activities

​

 

  ​

​

 

​

Purchases of Fixed Assets

​

 

(2,687,934)

​

 

(1,658,820)

Investments in Patents and Trademarks

​

 

(460,807)

​

 

(381,614)

Investments in Other Equity Assets

​

 

—

​

 

(50,000)

​

​

​

​

​

​

​

Net Cash Flows Used in Investing Activities

​

 

(3,148,741)

​

 

(2,090,434)

​

​

​

​

​

​

​

Cash Flows Provided by (Used in) Financing Activities

​

 

  ​

​

 

  ​

Proceeds from Sale of Preferred and Common Stock to Quanta

​

​

—

​

​

10,000,000

Proceeds from Exercise of Stock Options

​

 

—

​

 

106,843

Proceeds from ATM Program, Net

​

​

10,153,739

​

​

9,640,449

Preferred Dividends Paid

​

​

(114,923)

​

​

—

​

​

​

​

​

​

​

Net Cash Flows Provided by (Used in) Financing Activities

​

 

10,038,816

​

 

19,747,292

​

​

​

​

​

​

​

Net Increase (Decrease) in Cash and Cash Equivalents

​

 

(11,958,079)

​

 

4,422,023

Cash and Cash Equivalents - Beginning of Period

​

 

21,150,213

​

 

18,186,506

​

​

​

​

​

​

​

Cash and Cash Equivalents - End of Period

​

$

9,192,134

​

$

22,608,529

​

​

​

​

​

​

​

Supplemental Disclosures

​

 

  ​

​

 

​

Accrued Preferred Dividends included in Accrued Expenses

​

$

37,500

​

$

—

Depreciation and Amortization included in Research and Development Expense

​

​

889,277

​

​

574,511

Proceeds from ATM Program in Other Receivables

​

​

358,309

​

​

—

Purchases of Fixed Assets included in Accrued Expenses

​

​

—

​

​

1,165,418

​

The accompanying notes are an integral part of these consolidated financial statements.

​

​

6

Table of Contents

VUZIX CORPORATION

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Note 1 – Basis of Presentation

The accompanying unaudited consolidated financial statements of Vuzix Corporation (the “Company” or “Vuzix”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, the unaudited consolidated financial statements do not include all information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. The results of the Company’s operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results of the Company’s operations for the full fiscal year or any other period.

The accompanying interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto of the Company as of and for the year ended December 31, 2025, as reported in the Company’s Annual Report on Form 10-K filed with the SEC on March 12, 2026.

​

Customer Concentrations

For the three months ended September 30, 2026, two customers represented 22% and 10% of total product revenue and two customers represented 44% and 32% of engineering services revenue. For the three months ended September 30, 2025, four customers represented 19%, 17%, 11%, and 11% of total product revenue and four customers represented 39%, 32%, 16%, and 12% of engineering services revenue.

For the nine months ended September 30, 2026, one customer represented 17% of total product revenue and two customers represented 50% and 29% of engineering services revenue. For the nine months ended September 30, 2025, one customer represented 17% of total product revenue and four customers represented 29%, 25%, 23%, and 11% of engineering services revenue.

As of September 30, 2026, three customers represented 38%, 17%, and 13% of accounts receivable. As of December 31, 2025, two customers represented 55% and 35% of accounts receivable.

Fair Value of Financial Instruments

​

The Company’s financial instruments primarily consist of cash and cash equivalents, accounts receivable, accounts payable, unearned revenue, accrued expenses, and income and other taxes payable. As of the consolidated balance sheet dates, the estimated fair values of the financial instruments were not materially different from their carrying values as presented due to the short maturities of these instruments.

Going Concern 

​

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should we be unable to continue as a going concern.

In accordance with ASC Subtopic 205-40, Presentation of Financial Statements — Going Concern, management is required to evaluate whether conditions or events, considered in the aggregate, raise substantial doubt about the Company’s ability to continue as a going concern within twelve (12) months after the date that the financial statements are issued. The going concern assumption underlies all GAAP financial reporting and presumes that the

7

Table of Contents

Company will continue normal business operations into the foreseeable future, unless such conditions or events raise substantial doubt about the Company’s ability to continue as a going concern. 

​

Additional disclosure is required when there is substantial doubt about business continuity or substantial doubt that has not been alleviated by management’s mitigation plans. As required under applicable accounting standards, management has concluded that substantial doubt may exist surrounding the Company's ability to meet its obligations within twelve (12) months of the release of the financial statements.

​

The Company incurred net losses of $23,086,207 for the nine months ended September 30, 2026; $32,273,128 for the year ended December 31, 2025; and $73,538,157 for the year ended December 31, 2024. The Company had net cash outflows from operations of $18,848,154 for the nine months ended September 30, 2026; $18,789,272 for the year ended December 31, 2025; and $23,739,372 for the year ended December 31, 2024. As of September 30, 2026, the Company had an accumulated deficit of $423,057,117.

The Company’s cash requirements going forward are primarily for funding operating losses, research and development, working capital, and investments in fixed assets, patents, and trademarks. Our cash requirements related to funding operating losses depend upon numerous factors, including new product development activities, research and development costs, our ability to commercialize our products, our products’ timely market acceptance, selling prices and gross margins, and other factors. Historically, the Company has met its cash needs primarily through the sale of equity securities. The Company will need to grow its business significantly to become profitable and self-sustaining on a cash flow basis or it will be required to cut its operating costs significantly or raise new equity and/or debt capital.

​

These historical financial factors initially raise doubt about the Company’s ability to continue as a going concern. Management intends to take actions necessary to continue as a going concern, as discussed herein. Management’s plans to alleviate the conditions that raise doubt include raising further capital, the implementation of operational improvements, and the curtailment of certain development programs, all of which the Company expects will preserve cash.

​

Management’s plans concerning these matters and managing our liquidity include, among other things:    

●Delaying or curtailing discretionary and non-essential operating expenses and investments in fixed assets not related to near-term product and manufacturing needs and reducing other investing activities for the remainder of our 2026 and 2027 fiscal years;
●The expected gross margin contributions once we are successful in securing volume manufacturing and sales of waveguides from our newly expanded waveguide manufacturing plant, particularly to new smart glasses ODM/OEM customers and future co-packaged optics (“CPO”) AI data center customers; and
●Continued pursuit of licensing and strategic opportunities around our waveguide for imaging and CPO applications and other waveguide technologies with potential ODMs/OEMs, which may include the receipt of upfront licensing fees and on-going supply agreements.

The Company has historically raised capital through the sale of equity securities. The Company filed a Registration Statement on Form S-3 that became effective in May 2024, which included an initial sales agreement prospectus for the issuance and sale of up to $50,000,000 of our common stock from time to time under this sales agreement with an investment bank in an “at the market” offering. Subsequently, in August 2026, the Company entered into a new sales agreement with the same investment bank for the issuance of up to $100,000,000 of our common stock and all remaining unused issuance under the prior sales agreement, totaling $16,330,382, were terminated. Since May 2024, the Company has raised $32,978,341, net of broker expenses, including $10,512,048 during the nine months ended September 30, 2026, under these sales agreements.

Management will continue to utilize the available “at the market” offering noted above to satisfy obligations as they become due, as well as, monitor the capital markets on an ongoing basis and may consider raising capital under other programs if favorable market conditions develop. If the Company needs to raise capital for additional liquidity, the Company may be required to pursue additional equity financing, further curtail expenses, or enter into one or more strategic

8

Table of Contents

transactions. However, management can make no assurance that the Company will be able to successfully complete any of the aforementioned pursuits on terms acceptable to the Company, or at all.

As a result of management’s plan above, our current amount of cash on hand, and our historical ability to raise capital, management has concluded that doubt of our ability to continue as a going concern has been alleviated.

​

Use of Estimates

​

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at year-end and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Segment Data, Geographic Information and Significant Customers

Operating segments are defined as components of an entity for which separate financial information is available and regularly reviewed by the chief operating decision maker (“CODM”). The Company’s CODM is its Chief Executive Officer. The Company is not organized by market and is managed and operated as one business. A single management team that reports to the CODM comprehensively manages the entire business. The Company does not operate any material separate lines of business or separate business entities and therefore manages its operations as a single operating segment and, therefore, a single reportable segment. Our CODM evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis, accompanied by information about revenue disaggregated by geographic region. Because our CODM evaluates financial performance on a consolidated basis, we have determined that we have a single operating segment composed of the consolidated financial results of Vuzix Corporation.

​

The CODM reviews financial information, presented on a consolidated basis, focusing on significant expenses and net loss/income for purposes of making operating decisions, allocating resources, and evaluating financial performance. The primary measure used by our CODM to assess performance and make operating decisions is net loss as reported on our consolidated statements of operations. Net loss is used by our CODM to identify underlying trends in the performance of our business and make comparisons with the financial performance of our competitors. The measure of segment assets is reported on the balance sheet as total consolidated assets. Our CODM also reviews total assets, as reported on our consolidated balance sheets, and purchases of fixed assets, as reported on our consolidated statements of cash flows in determining overall financial strength and operating prioritizations.

​

9

Table of Contents

Significant expenses regularly provided to and reviewed by the CODM are Cost of Sales, Research and Development, General and Administrative, and Total Compensation. These segment items for the three and nine months ended September 30, 2026 and 2025 are:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended
September 30,

​

Nine Months Ended
September 30,

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

​

​

​

​

​

​

​

​

​

​

​

​

​

Sales

​

$

714,449

​

$

1,160,947

​

$

3,219,263

​

$

4,037,598

​

​

​

​

​

​

​

​

​

​

​

​

​

Less expenses:

​

​

​

​

​

​

​

​

​

​

​

​

Cost of Sales, excluding compensation

​

​

(1,009,281)

​

​

(1,161,854)

​

​

(3,691,749)

​

​

(4,219,187)

Research and Development, excluding compensation

​

​

(1,563,208)

​

​

(1,475,858)

​

​

(4,497,608)

​

​

(3,870,517)

General and Administrative, excluding compensation

​

​

(1,313,117)

​

​

(1,301,298)

​

​

(3,686,634)

​

​

(4,417,010)

Total Compensation

​

​

(4,306,878)

​

​

(4,043,040)

​

​

(12,513,966)

​

​

(13,212,176)

Other Segment Items

​

​

(908,153)

​

​

(533,122)

​

​

(1,915,513)

​

​

(1,976,814)

​

​

​

(9,100,637)

​

​

(8,515,172)

​

​

(26,305,470)

​

​

(27,695,704)

​

​

​

​

​

​

​

​

​

​

​

​

​

Net Loss

​

$

(8,386,188)

​

$

(7,354,225)

​

$

(23,086,207)

​

$

(23,658,106)

​

Other Segment Items:

-Selling and Marketing, excluding compensation expense;
-Depreciation and Amortization, not included in Cost of Sales; and
-Other Income.

Geographic Information

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30,

​

2026

​

​

​

​

2025

​

​

Revenue

  ​ ​ ​

% of Total

  ​ ​ ​

​

​

  ​ ​ ​

Revenue

  ​ ​ ​

% of Total

  ​ ​ ​

U.S.

$

551,136

 

77

%  

​

U.S.

​

$

1,001,990

 

86

%  

Germany

 

34,167

 

5

%  

​

Switzerland

​

 

41,372

 

4

%  

Canada

​

29,478

​

4

%

​

Japan

​

​

29,414

​

3

%  

Others

 

99,668

 

14

%  

​

Others

​

 

88,171

 

7

%  

Total Revenues

$

714,449

 

100

%  

​

Total Revenues

​

$

1,160,947

 

100

%  

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30,

​

2026

​

​

​

​

2025

​

​

Revenue

  ​ ​ ​

% of Total

  ​ ​ ​

​

​

  ​ ​ ​

Revenue

  ​ ​ ​

% of Total

  ​ ​ ​

U.S.

$

2,365,967

 

74

%  

​

U.S.

​

$

2,470,637

 

61

%  

Switzerland

 

166,857

 

5

%  

​

Netherlands

​

 

574,023

 

14

%  

Japan

 

159,263

 

5

%  

​

Hungary

​

 

189,534

 

5

%  

Others

 

527,176

 

16

%  

​

Others

​

 

803,404

 

20

%  

Total Revenues

$

3,219,263

 

100

%  

​

Total Revenues

​

$

4,037,598

 

100

%  

​

All long-lived assets other than limited amounts of certain product manufacturing tooling utilized at our manufacturing vendors are located in the U.S.

10

Table of Contents

Recently Adopted Accounting Pronouncements

​

The Company adopted ASU 2025-05 FASB Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets as of January 1, 2026. The guidance provides a practical expedient for estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under ASC 606. The Company elected to apply the practical expedient in estimating expected credit losses on its applicable financial assets. The adoption of ASU 2025-05 did not have a material impact on the Company’s consolidated financial statements or related disclosures.

​

Recent Accounting Pronouncements

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income (Topic 220): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires public entities to provide disaggregated disclosures of certain expense captions presented on the face of the income statement into specific categories within the notes to the consolidated financial statements. ASU 2024-03 is effective for the Company’s annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The ASU may be applied either on a prospective or retrospective basis. The Company is currently evaluating the impact of adoption of ASU 2024-03 on its financial statements and related disclosures.

​

Note 2 – Revenue Recognition and Contracts with Customers

Disaggregated Revenue

The Company’s total revenue was comprised of two major product lines: Products Sales (which include smart glasses, software, and accessories) and Engineering Services (which include engineering services fees and related ODM/OEM services and product sales, as well as waveguide and display engine component sales).

​

The following table summarizes the revenue recognized by major product line:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

​

September 30, 

​

September 30, 

​

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

Revenues

 

​

  ​

 

​

  ​

 

​

  ​

 

​

  ​

 

Products Sales

​

$

494,141

​

$

896,274

​

$

2,420,816

​

$

3,265,657

​

Engineering Services

​

 

220,308

​

 

264,673

​

 

798,447

​

 

771,941

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Total Revenue

​

$

714,449

​

$

1,160,947

​

$

3,219,263

​

$

4,037,598

​

​

Significant Judgments

Under Topic 606 “Revenue from Contracts with Customers”, we use judgments that could potentially impact both the timing of our satisfaction of performance obligations and our determination of transaction prices used in determining revenue recognized by major product line. Such judgments include considerations in determining our transaction prices and when our performance obligations are satisfied for our standard product sales. For Engineering Services, performance obligations are recognized over time using the input method, and the estimated costs to complete each project are considered significant judgments.

Performance Obligations

Revenues from our performance obligations are typically satisfied at a point-in-time for Product Sales, which are recognized when the customer obtains control and ownership, which is generally upon shipment. The Company considers shipping and handling activities performed to be fulfillment activities and not a separate performance obligation. The Company also records revenue for performance obligations relating to our Engineering Services both at a point-in-time and over time. For those performance obligations recognized over time, the input method is utilized for

11

Table of Contents

measuring progress toward satisfying the performance obligations. Satisfaction of these performance obligations is measured by the Company’s costs incurred as a percentage of total expected costs to project completion, as the inputs of actual costs incurred by the Company are directly correlated with progress toward completing the contract. As such, the Company believes that our methodologies for recognizing revenue both at a point-in-time and over time for our Engineering Services correlate directly with the transfer of control of the underlying assets to our customers.

Our standard product sales include a twelve (12) month assurance-type product warranty. In the case of certain ODM/OEM products and waveguide sales, some include a standard product warranty of up to eighteen (18) months to allow distribution channels to offer the end customer a full twelve (12) months of coverage. We offer an extended warranty to customers that extends the standard product warranty on product sales for an additional twelve (12) month period. All revenue related to extended product warranty sales is deferred and recognized over the extended warranty period. Our Engineering Services contracts vary from contract to contract but typically include payment terms of Net 30 days from the date of billing, subject to an agreed upon customer acceptance period.

As of September 30, 2026 and December 31, 2025, there were nil and $47,025, respectively, in outstanding performance obligations remaining for extended warranties.

The following table presents a summary of the Company’s sales by revenue recognition method as a percentage of total net sales for the three and nine months ended September 30, 2026 and 2025:

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Three Months Ended
September 30,

​

​

Nine Months Ended
September 30,

​

​

​

2026

 

2025

 

​

2026

 

2025

 

Point-in-Time

 

88

%

77

%

​

84

%

82

%

Over Time – Input Method

 

12

%

23

%

​

16

%

18

%

​

​

​

​

​

​

​

​

​

​

​

Total

 

100

%

100

%

​

100

%

100

%

​

Remaining Performance Obligations

As of September 30, 2026, the Company had $1,810,495 of remaining performance obligations under current waveguide and other development projects, including initial product production, which represents the remainder of transaction prices totaling $3,650,000 under these development projects, which commenced in 2023 and 2026, less revenue recognized under percentage of completion to date. The Company expects to recognize the remaining revenue related to these projects, based upon the following expected due dates: 2% in 2026, 45% in 2027, and 53% in 2028. Revenues earned less amounts invoiced at September 30, 2026, in the amount of $539,505, are reflected as Accrued Revenues in Excess of Billings in the accompanying Consolidated Balance Sheet.

As of December 31, 2025, the Company had $1,836,670 of remaining performance obligations under current waveguide and other development projects, which represented the remainder of transaction prices totaling $3,737,168 under these development projects less revenue recognized under percentage of completion to date.

As of September 30, 2026, the Company had no material outstanding performance obligations related to product sales, other than its standard and extended product warranties.

​

12

Table of Contents

Note 3 – Loss Per Share

Basic earnings per share is computed by dividing net income (loss) less preferred dividends, whether paid or accrued, on any outstanding preferred stock by the weighted average number of common shares outstanding for the period. Diluted earnings per share calculations reflect the assumed exercise of all dilutive employee stock options, vesting of Restricted Stock Units (“RSUs”), and Performance Stock Units (“PSUs”) applying the treasury stock method promulgated by FASB ASC Topic 260, “Earnings Per Share” and the conversion of any outstanding convertible preferred shares that are in-the-money, applying the as-if-converted method. However, if the assumed exercise of stock options, RSUs, PSUs, and the conversion of any preferred shares are anti-dilutive, basic and diluted earnings per share are the same for all periods. As a result of the net losses for the three and nine months ended September 30, 2026 and 2025, all outstanding instruments would be anti-dilutive. As of September 30, 2026 and 2025, there were 10,368,623 and 10,664,321 common stock share equivalents, respectively, potentially issuable from the exercise of stock options, vesting of RSUs and awarded PSUs, and the conversion of preferred stock that could dilute basic earnings per share in the future.

​

​

Note 4 – Inventories, Net

Inventories are stated at the lower of cost and net realizable value, and consist of the following:

​

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

​

​

​

​

​

​

​

Purchased Parts and Components

​

$

5,244,350

​

$

5,369,273

Work-in-Process

​

 

182,662

​

 

198,207

Finished Goods

​

 

2,749,410

​

 

2,689,458

Less: Reserve for Obsolescence

​

 

(5,946,807)

​

 

(6,068,188)

​

​

​

​

​

​

​

Inventories, Net

​

$

2,229,615

​

$

2,188,750

​

​

During the nine months ended September 30, 2026 and 2025, the Company disposed of nil and $1,307,662, respectively, of inventory that was fully provisioned for as obsolete in the previous year.

​

Note 5 – Fixed Assets

Fixed Assets consisted of the following:

​

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Tooling and Manufacturing Equipment

​

$

12,547,067

​

$

10,348,958

Leasehold Improvements

​

 

3,129,906

​

 

2,809,745

Computers and Purchased Software

​

 

740,522

​

 

612,524

Furniture and Equipment

​

 

2,546,374

​

 

2,502,286

​

​

 

18,963,869

​

 

16,273,513

Less: Accumulated Depreciation

​

 

(9,841,148)

​

 

(8,647,275)

Fixed Assets, Net

​

$

9,122,721

​

$

7,626,238

​

Total depreciation expense for fixed assets for the three months ended September 30, 2026 and 2025, was $444,071 and $372,241, respectively. Total depreciation expense for fixed assets for the nine months ended September 30, 2026 and 2025, was $1,193,873 and $1,096,081, respectively.

As of September 30, 2026 and December 31, 2025, there were $3,611,417 and $2,602,784, respectively, of waveguide related manufacturing fixed assets that are not yet placed into service and, therefore, are not currently being depreciated.

13

Table of Contents

Note 6 – Patents and Trademarks

Patents and Trademarks consisted of the following:

​

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Patents and Trademarks

​

$

5,289,080

​

$

4,841,560

Less: Accumulated Amortization

​

 

(1,623,132)

​

 

(1,482,494)

Patents and Trademarks, Net

​

$

3,665,948

​

$

3,359,066

​

Total amortization expense for patents and trademarks for the three months ended September 30, 2026 and 2025 was $52,478 and $52,093, respectively. Total amortization expense for patents and trademarks for the nine months ended September 30, 2026 and 2025 was $153,924 and $146,747, respectively. The estimated aggregate annual amortization expense for each of the next five fiscal years is approximately $244,000.

Note 7 – Technology Licenses, Net

​

Technology Licenses consisted of the following:

​

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

​

​

​

​

​

​

​

Licenses

​

$

2,443,356

​

$

2,443,356

Write-Offs

​

 

(794,889)

​

 

—

Less: Accumulated Amortization

​

 

(1,239,297)

​

 

(1,883,383)

Licenses, Net

​

$

409,170

​

$

559,973

​

Total amortization expense related to technology licenses for the three months ended September 30, 2026 and 2025 was $50,268 and $50,269, respectively. Total amortization expense related to technology licenses for the nine months ended September 30, 2026 and 2025 was $150,802 and $150,803, respectively. The estimated aggregate annual amortization expense for each of the next two fiscal years is approximately $164,000.

During the three months ended September 30, 2026, the Company retired two technology licenses that were no longer in use that were fully amortized. As the licenses were fully amortized at the time of disposal, the retirement resulted in no gain or loss and had no impact on the Company’s results of operations.

Note 8 - Other Assets

The Company’s Other Assets were as follows:

​

​

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Investments (fair value not readily determinable)

​

$

300,000

​

$

650,000

Additions

​

​

—

​

​

50,000

Write-offs

​

​

—

​

​

(400,000)

Total Investments (at cost)

​

​

300,000

​

​

300,000

​

​

​

​

​

​

​

Software Development Costs

​

​

1,000,000

​

​

1,000,000

Additions

​

​

—

​

​

—

Less: Accumulated Amortization

​

​

(1,000,000)

​

​

(972,222)

Software Development Costs, Net

​

​

—

​

​

27,778

​

​

​

​

​

​

​

Total Other Assets

​

$

300,000

​

$

327,778

​

14

Table of Contents

Total amortization expense related to all software updates, included in cost of sales in 2025 and now fully amortized, for the three months ended September 30, 2026 and 2025 was nil and $41,668, respectively. Total amortization expense related to all software updates for the nine months ended September 30, 2026 and 2025 was $27,778 and $125,001, respectively.

​

Note 9 – Accrued Expenses

Accrued expenses consisted of the following:

​

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

​

​

​

​

​

​

​

Accrued Product Development and Tooling Costs

​

$

804,722

​

$

2,416,910

Accrued Wages and Related Costs

​

 

359,067

​

 

756,933

Accrued Professional Services

​

 

147,692

​

 

213,712

Accrued Warranty Obligations

​

 

62,818

​

 

55,637

Other Accrued Expenses

​

 

541,827

​

 

147,215

​

​

​

​

​

​

​

Total

​

$

1,916,126

​

$

3,590,407

​

The Product Development and Tooling Costs of $804,722 at September 30, 2026 have been previously expensed as research and development expense or were capitalized as manufacturing assets, primarily in our 2025 fiscal year. The remaining capitalized tooling costs portion will be amortized and the deferred development expense portion will be paid to the vendor over the related product’s future production of a specified number of units.

The Company has warranty obligations in connection with the sale of certain of its products. The warranty period for its products is generally twelve (12) months, unless the customer purchases an extended warranty for an additional twelve (12) months. The costs incurred to provide for these warranty obligations are estimated and recorded as an accrued liability at the time of sale. The Company estimates its future warranty costs based upon product-based historical performance rates and related costs to repair.

The changes in the Company’s accrued warranty obligations for the nine months ended September 30, 2026, were as follows:

​

​

​

​

​

Accrued Warranty Obligations at December 31, 2025

​

$

55,637

Reductions for Settling Warranties

​

 

(65,443)

Warranties Issued During Period

​

 

72,624

​

​

​

​

Accrued Warranty Obligations at September 30, 2026

​

$

62,818

​

​

Note 10 – Income Taxes

The Company’s effective income tax rate differs from the U.S. statutory rate primarily due to the valuation allowance recorded against deferred tax assets.

​

15

Table of Contents

Note 11 – Mezzanine Equity and Stockholders’ Equity

Preferred Stock

The Board of Directors is authorized to establish and designate different series of preferred stock and to fix and determine their voting powers and other rights and terms. The Company has 5,000,000 authorized shares of preferred stock with a par value of $0.001 as of September 30, 2026 and December 31, 2025. Of this total, 49,626 shares are designated as Series A Preferred Stock and 800,000 shares are designated as Series B Convertible Preferred Stock (“Series B Preferred Stock”). There were nil shares of Series A Preferred Stock issued and outstanding on September 30, 2026 and December 31, 2025, and there were 419,959 shares of Series B Preferred Stock issued and outstanding as of September 30, 2026 and December 31, 2025.

Each share of Series B Preferred Stock is convertible, at the option of the holder, into ten shares of common stock, subject to adjustment for stock splits, stock dividends, and similar transactions. The Company may, at its option at any time after notice, redeem the Series B Preferred Stock that is outstanding, subject to conversion rights of the holder. The Series B Preferred Stock does not entitle the holders to voting rights, except with respect to certain actions which require the consent of the holders of 66 2/3% of the outstanding shares of Series B Preferred Stock, or as required by law.

A summary of the Series B Preferred Stock issued through September 30, 2026 is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

Quanta Computer Investments

  ​ ​ ​

Series B Preferred Stock - Shares Issued

​

  ​ ​ ​

Series B Preferred Stock - Paid-in Capital

​

  ​ ​ ​

Series B Preferred Stock - Conversion Price

  ​ ​ ​

Common Stock to be issued upon Conversion

​

Tranche 2 or Second Closing

​

189,717

​

$

5,000,000

​

$

26.35

​

1,897,170

​

Tranche 3 or Third Closing

​

230,242

​

$

5,000,000

​

$

21.72

​

2,302,420

​

Totals

​

419,959

​

$

10,000,000

​

​

​

​

4,199,590

​

​

The Series B Preferred Stock entitles the holders to cumulative dividends at the annual rate of 1.5% of the original issuance price, payable quarterly in cash. During the three months ended September 30, 2026 and 2025, there were $37,500 and nil of preferred dividends paid, respectively. During the nine months ended September 30, 2026 and 2025, there were $114,923 and nil of preferred dividends paid, respectively. As of September 30, 2026 and December 31, 2025, total accumulated and unpaid preferred dividends were $37,500 and $39,923, respectively.

Holders of the Series B Preferred Stock will have the right upon the occurrence of certain triggering events, as defined in the certificate of designation, that are not all solely within the control of the Company to require the Company to redeem all or part of their Series B Preferred Stock for cash at a price equal to 100% of the liquidation preference plus accrued but unpaid dividends. Because the Series B Preferred Stock contains redemption features that are not solely within the control of the Company and may be triggered by events outside the Company’s control, the Series B Preferred Stock is classified outside of permanent equity, in accordance with ASC 480-10-S99-3A (SEC guidance on redeemable securities).

Common Stock

As of September 30, 2026, the Company’s authorized common stock consists of 200,000,000 shares, par value of $0.001. There were 85,227,031 shares issued and 84,647,359 shares outstanding as of September 30, 2026 and 81,679,367 shares issued and 81,099,695 shares outstanding as of December 31, 2025.

​

The 419,959 shares of Series B Preferred Stock outstanding as of September 30, 2026 held by Quanta are convertible into 4,199,590 shares of common stock.

​

16

Table of Contents

ATM Program

The Company filed a Registration Statement on Form S-3 with the SEC that became effective in May 2024, which currently includes a sales agreement prospectus for the issuance and sale of up to $50,000,000 of our common stock from time to time under a sales agreement with an investment bank in an “at the market” (“ATM”) offering. Subsequently, in August 2026, the Company entered into a new sales agreement with the same investment bank for the issuance of up to $100,000,000 of our common stock and all remaining unused issuance under the prior sales agreement, totaling $16,330,382, were terminated.

​

During the three months ended September 30, 2026, the Company sold 218,628 shares of common stock for gross proceeds of $620,166 (average sales price of $2.84 per share) under the ATM before deducting broker expenses paid by the Company of $22,328. During the three months ended September 30, 2025, the Company sold 1,903,120 shares of common stock for gross proceeds of $5,757,883 (average sales price of $3.03 per share) under the ATM before deducting broker expenses paid by the Company of $207,284.

​

During the nine months ended September 30, 2026, the Company sold 3,218,628 shares of common stock for gross proceeds of $10,904,616 (average sales price of $3.39 per share) under the ATM before deducting broker expenses paid by the Company of $392,568. During the nine months ended September 30, 2025, the Company sold 3,206,855 shares of common stock for gross proceeds of $10,000,466 (average sales price of $3.12 per share) under the ATM before deducting broker expenses paid by the Company of $360,017.

​

To-date in the fourth quarter of 2026, the Company sold 496,487 shares of common stock for gross proceeds of $1,495,555 (average of $3.01 per share) under the ATM before deducting broker expenses paid by the Company of $53,840.

​

The Company is using the net proceeds from these sales for general corporate purposes, including working capital.

​

Note 12 – Stock-Based Compensation

A summary of stock option activity related to the Company’s employee equity incentive plan for the nine months ended September 30, 2026, is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

Average

​

​

Number of

​

Average

​

Remaining Life

​

  ​ ​ ​

Options

  ​ ​ ​

Exercise Price

  ​ ​ ​

(years)

Outstanding at December 31, 2025

 

3,988,858

​

$

3.86

 

7.04

Granted

 

20,000

​

 

3.10

 

  ​

Exercised

 

(269,369)

​

 

1.62

 

  ​

Expired or Forfeited

 

(99,929)

​

 

4.67

 

  ​

​

​

​

​

​

​

​

​

Outstanding at September 30, 2026

 

3,639,560

​

$

4.00

 

6.19

​

The weighted average remaining contractual term for all options as of September 30, 2026 and December 31, 2025, was 6.19 years and 7.04 years, respectively.

As of September 30, 2026, there were 3,521,784 options that were fully vested and exercisable at a weighted average exercise price of $4.05 per share. The weighted average remaining contractual term of the vested options is 6.09 years.

As of September 30, 2026, there were 117,776 unvested options with a weighted average exercise price of $2.73 per share. The weighted average remaining contractual term of the unvested options is 8.50 years.

17

Table of Contents

A summary of RSA, RSU, and PSU activity related to the Company’s employee equity incentive plan, excluding contingently issuable bonus PSU awards, as discussed below, for the nine months ended September 30, 2026, is as follows:

​

​

​

​

​

​

​

​

​

​

​

Weighted Average

Restricted Stock Awards and Restricted Stock Units

​

Number of

​

Grant Date

​

  ​ ​ ​

Shares/Units

  ​ ​ ​

Fair Value Per Share/Unit

Unvested at December 31, 2025

 

772,438

​

$

2.61

Granted

 

1,030,238

​

 

2.50

Vested

 

(251,027)

​

 

2.40

Forfeited

 

(48,334)

​

 

2.35

​

​

​

​

​

​

Unvested at September 30, 2026

 

1,503,315

​

$

2.58

​

​

​

​

​

​

​

​

​

​

​

Weighted Average

Performance Stock Units

​

Number of

​

Grant Date

​

  ​ ​ ​

Units

  ​ ​ ​

Fair Value Per Unit

Unvested at December 31, 2025

 

1,504,431

​

$

2.37

Granted

 

637,946

​

 

2.40

Vested

 

(74,257)

​

 

3.15

Forfeited

 

(1,041,962)

​

 

2.16

​

​

​

​

​

​

Unvested at September 30, 2026

 

1,026,158

​

$

2.55

​

On April 24, 2026, the Company issued 593,797 RSUs and 302,727 PSUs to all non-executive employees of the Company. The fair market value on the date of award of the RSUs and PSUs was $2.39 per unit. The RSUs will vest over time at a rate of one-third annually on each December 15, 2026, 2027, and 2028. The PSUs will vest upon the achievement of certain revenue and EBITDA targets before December 31, 2028. As of September 30, 2026, these targets are considered probable and the associated expense is being amortized. If both the revenue and EBITDA targets are exceeded by 150%, an additional 151,364 PSUs could be issued and vest immediately. As of September 30, 2026, these bonus targets are not considered probable and their fair market value is not being amortized in stock-based compensation expense.

On April 29, 2026, the Company issued 335,218 RSUs and 335,218 PSUs to its CEO and CFO. The fair market value on the date of award of the RSUs and PSUs was $2.41 per unit. The RSUs will vest over time at a rate of one-third annually on each December 15, 2026, 2027, and 2028. The PSUs will vest upon the achievement of certain revenue and EBITDA targets before December 31, 2028. As of September 30, 2026, these targets are considered probable and the associated expense is being amortized. If both the revenue and EBITDA targets are exceeded by 150%, an additional 167,609 PSUs could be issued and vest immediately. As of September 30, 2026, these bonus targets are not considered probable and their fair market value is not being amortized in stock-based compensation expense.

​

During the nine months ended September 30, 2026, the Company issued 88,236 RSUs to its independent board members as part of their annual retainer for services covering the period of July 2026 to June 2027. The fair market value on the date of award of the RSUs issued was $3.40, resulting in an aggregate fair value of approximately $300,000. The fair market value of these awards is expensed over twelve (12) months, which began on July 1, 2026.

​

For the three months ended September 30, 2026 and 2025, the Company recorded total stock-based compensation expense, including stock awards but excluding stock option awards under the Company’s former LTIP, of $881,465 and $765,955, respectively. For the nine months ended September 30, 2026 and 2025, the Company recorded total stock-based compensation expense, including stock awards but excluding stock option awards under the Company’s former LTIP, of $2,174,379 and $3,311,353, respectively.

​

As of September 30, 2026, the Company had $4,593,146 of unrecognized stock-based compensation expense related to all stock options, RSAs, RSUs, and PSUs considered probable, which will be recognized over a weighted average period of 1.9 years.

18

Table of Contents

​

For the nine months ended September 30, 2025, the Company recorded non-cash stock-based compensation expense of $1,180,356 for the former LTIP options that vested or were probable to vest, prior to their cancellation effective June 16, 2025.

​

These expenses are presented in the same financial statement line items in the Statements of Operations as the cash-based compensation expenses for the same recipients.

​

Note 13 – Right-of-Use Assets and Liabilities

Future lease payments under operating leases as of September 30, 2026, were as follows:

​

​

​

​

​

2026

​

$

141,796

2027

​

 

519,919

Total Future Lease Payments

​

 

661,715

Less: Imputed Interest

​

 

(51,234)

Total Lease Liability Balance

​

$

610,481

​

Operating lease costs under the operating leases totaled $190,450 and $284,386 for the three months ended September 30, 2026 and 2025, respectively. Operating lease costs under the operating leases totaled $673,937 and $777,505 for the nine months ended September 30, 2026 and 2025, respectively.

​

As of September 30, 2026, the weighted average discount rate was 7.1% and the weighted average remaining lease term was 1.2 years.

​

​

​

​

Note 14 – Litigation

We are involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. In connection with these matters, we assess, on a regular basis, the probability and range of possible loss based upon the developments in these matters. A liability is recorded in the consolidated financial statements if the Company believes it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review outstanding legal matters to determine the adequacy of the liabilities accrued and related disclosures in consideration of many factors, which include, but are not limited to, past history, scientific and other evidence, and the specifics and status of each matter. We may change our estimates if our assessment of the various factors changes and the amount of ultimate loss may differ from our estimates, resulting in a material effect on our business, financial condition, results of operations, and/or cash flows. With respect to these matters, based upon management’s current knowledge, the Company believes that the amount or range of any reasonably possible loss, if any, will not, either individually or in the aggregate, have a material adverse effect on the Company’s financial position, results of operations or cash flows.

​

The Company is not currently party to, nor is its property subject to, any material legal proceedings.

​

​

19

Table of Contents

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of financial condition and results of operations in conjunction with the financial statements and related notes appearing elsewhere in this quarterly report and in our Annual Report on Form 10-K for the year ended December 31, 2025.

As used in this report, unless otherwise indicated, the terms “Company,” “Vuzix”, “management,” “we,” “our,” and “us” refer to Vuzix Corporation.

Critical Accounting Policies and Significant Developments and Estimates

The discussion and analysis of our financial condition and results of operations is based upon our unaudited consolidated financial statements and related notes appearing elsewhere in this quarterly report. The preparation of these statements in conformity with GAAP requires the appropriate application of certain accounting policies, many of which require us to make estimates and assumptions about future events and their impact on amounts reported in our consolidated financial statements, including the statement of operations, balance sheet, cash flow and related notes. We continually evaluate our estimates used in the preparation of our financial statements, including those related to revenue recognition, allowance for credit losses, inventories, warranty reserves, product warranty, carrying value of long-lived assets, fair value measurement of financial instruments, valuation of stock compensation awards, and income taxes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not apparent from other sources. Since future events and their impact cannot be determined with certainty, the actual results will inevitably differ from our estimates. Such differences could be material to the consolidated financial statements.

We believe that our application of accounting policies, and the estimates inherently required therein, are reasonable. We periodically re-evaluate these accounting policies and estimates and make adjustments when facts and circumstances dictate. Historically, we have found our application of accounting policies to be appropriate, and actual results have not differed materially from those determined using such necessary estimates.

Management believes certain factors and trends are important in understanding our financial performance. The critical accounting policies, judgments and estimates we believe have the most significant effect on our consolidated financial statements are:

●Valuation of inventories;
●Going concern;
●Evaluation of liabilities to equity and derivatives;
●Investments in equity securities;
●Carrying value of long-lived assets, goodwill and other intangible assets;
●Software development costs;
●Revenue recognition;
●Product warranty;
●Stock-based compensation; and
●Income taxes.

20

Table of Contents

Our accounting policies are more fully described in the notes to our consolidated financial statements included in this quarterly report and in our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no significant changes in our accounting policies for the nine months ended September 30, 2026.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, an effect on our financial condition, financial statements, revenues or expenses.

Business Matters

We are engaged in the design, manufacture, marketing and sale of wearable display devices also referred to as head mounted displays (or HMDs), or near-eye displays, in the form of AI powered Smart Glasses. We also design, manufacture and sell imaging waveguides and related display engines for see-through AI Smart Glasses and heads-up displays (or HUDs), and we are developing waveguide-based optical interconnect components for CPO used for data transmission applications within data center server racks. We also develop other hardware related Augmented Reality (AR) technologies.

Our Smart Glasses are worn like eyeglasses or attach to a head worn mount. These AI Smart Glasses devices typically include cameras, sensors, and a computer that enable the user to view, record and interact with video and digital content, such as computer data, the Internet, social media or entertainment applications. Our wearable display products integrate microdisplay technology with our advanced optics to produce compact high-resolution display engines, which when viewed through our waveguide AI Smart Glasses products create virtual images that appear comparable in size to that of a computer monitor overlaid on the real world of their wearer.

For our Smart Glasses and AI/AR products, we are focused on enterprise, defense, medical, and security applications. The wearable display and mobile device markets in which we compete have been subject to rapid technological change over the last decade and as a result we must continue to improve our products’ performance and lower our costs. We believe our technology, intellectual property portfolio and position in the marketplace give us a leadership position in AI and AR Smart Glasses products, and imaging waveguide optics for AR glasses and HUDs, along with their related display engine technology. We also believe our waveguide technology positions us to address the emerging market for optical interconnect components within AI computing racks.

Recent Accounting Pronouncements

See Note 1 to the Unaudited Consolidated Financial Statements.

21

Table of Contents

Results of Operations

Comparison of Three Months Ended September 30, 2026 and 2025

The following table compares the Company’s consolidated statements of operations data for the three months ended September 30, 2026 and 2025:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30, 

 

​

  ​ ​ ​

​

​

  ​ ​ ​

​

​

  ​ ​ ​

Dollar

  ​ ​ ​

% Increase

 

​

​

2026

​

2025

​

Change

​

(Decrease)

 

​

​

​

​

​

​

​

​

​

​

​

​

​

Sales:

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Sales of Products

​

$

494,141

 

$

896,274

 

$

(402,133)

 

(45)

%

Sales of Engineering Services

​

 

220,308

 

​

264,673

 

​

(44,365)

 

(17)

%

​

​

 

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Total Sales

​

 

714,449

 

​

1,160,947

 

​

(446,498)

 

(38)

%

​

​

 

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Cost of Sales:

​

 

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Cost of Sales - Products

​

 

1,236,356

 

​

1,240,310

 

​

(3,954)

 

(0)

%

Cost of Sales - Depreciation and Amortization

​

 

84,063

 

​

180,927

 

​

(96,864)

 

(54)

%

Cost of Sales - Engineering Services

​

 

261,607

 

​

151,017

 

​

110,590

 

73

%

​

​

 

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Total Cost of Sales

​

 

1,582,026

 

​

1,572,254

 

​

9,772

 

1

%

​

​

 

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Gross Loss

​

 

(867,577)

 

​

(411,307)

 

​

(456,270)

 

111

%

Gross Loss%

​

 

(121)

%  

​

(35)

%  

​

  ​

 

  ​

​

​

​

 

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Operating Expenses:

​

 

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Research and Development

​

 

3,317,509

 

​

2,935,971

 

​

381,538

 

13

%

Selling and Marketing

​

 

1,640,931

 

​

1,147,194

 

​

493,737

 

43

%

General and Administrative

​

 

2,487,899

 

​

2,575,087

 

​

(87,188)

 

(3)

%

Depreciation and Amortization

​

 

163,458

 

​

424,335

 

​

(260,877)

 

(61)

%

​

​

 

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Loss from Operations

​

 

(8,477,374)

 

​

(7,493,894)

 

​

(983,480)

 

13

%

​

​

 

  ​

 

​

  ​

 

​

  ​

 

​

​

Other Income (Expense):

​

 

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Investment Income

​

 

108,029

 

​

156,760

 

​

(48,731)

 

(31)

%

Other Taxes

​

 

(14,000)

 

​

—

 

​

(14,000)

 

NM

​

Foreign Exchange Loss

​

 

(2,843)

 

​

(17,091)

 

​

14,248

 

(83)

%

​

​

 

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Total Other Income, Net

​

 

91,186

 

​

139,669

 

​

(48,483)

 

(35)

%

​

​

 

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Net Loss

​

$

(8,386,188)

​

$

(7,354,225)

​

$

(1,031,963)

 

14

%

​

Sales.   There was a decrease in total sales for the three months ended September 30, 2026, compared to the same period in 2025 of $446,498, or 38%. The following table reflects the major components of our sales:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​ ​

Three Months Ended

  ​ ​ ​

% of

  ​ ​ ​

Three Months Ended

  ​ ​ ​

% of

  ​ ​ ​

Dollar

  ​ ​ ​

% Increase

 

​

​

September 30, 2026

​

Total Sales

​

September 30, 2025

​

Total Sales

​

Change

​

(Decrease)

​

Sales of Products

​

$

494,141

 

69

%  

$

896,274

 

77

%  

$

(402,133)

 

(45)

%

Sales of Engineering Services

​

 

220,308

 

31

%  

 

264,673

 

23

%  

 

(44,365)

 

(17)

%

Total Sales

​

$

714,449

 

100

%  

$

1,160,947

 

100

%  

$

(446,498)

 

(38)

%

​

Sales of products decreased by 45%, or $402,133 for the three months ended September 30, 2026, compared to the same period in 2025. Reduced Smart Glasses revenue was the primary driver of this decrease as unit sales of our

22

Table of Contents

M400 product decreased, along with the unit sales of our products that were discontinued in 2025, compared to the previous year’s comparable period.

​

Sales of engineering services and OEM products for the three months ended September 30, 2026, were $220,308 compared to $264,673 in the comparable 2025 period, a decrease of 17% and primarily related to the timing of progress on customer projects.

Cost of Sales and Gross Loss. Cost of product revenues and engineering services are comprised of materials, components, labor, warranty costs, freight costs, manufacturing overhead, software royalties, the depreciation for our tooling and manufacturing equipment, and amortization of software development costs related to the production of our products and rendering of engineering services. The following table reflects the components of our cost of sales:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Three Months Ended

  ​ ​ ​

% of

  ​ ​ ​

Three Months Ended

  ​ ​ ​

% of

  ​ ​ ​

Dollar

  ​ ​ ​

% Increase

​

​

​

September 30, 2026

​

Total Sales

​

September 30, 2025

​

Total Sales

​

Change

​

(Decrease)

​

Product Cost of Sales

​

$

446,136

​

61

%  

$

727,316

​

63

%  

$

(281,180)

​

(39)

%

Manufacturing Overhead - Unapplied

 

​

790,220

 

111

%  

​

512,994

 

44

%  

​

277,226

 

54

%

Depreciation and Amortization

​

​

84,063

​

12

%  

​

180,927

​

16

%  

​

(96,864)

​

(54)

%

Engineering Services Cost of Sales

 

​

261,607

 

37

%  

​

151,017

 

12

%  

​

110,590

 

73

%

​

 

​

  ​

 

  ​

 

​

  ​

 

  ​

 

​

  ​

 

  ​

​

Total Cost of Sales

​

$

1,582,026

 

221

%  

$

1,572,254

 

135

%  

$

9,772

 

1

%

​

​

 

  ​

 

  ​

​

 

  ​

 

  ​

​

 

  ​

 

  ​

​

Gross Loss

​

$

(867,577)

 

(121)

%  

$

(411,307)

 

(35)

%  

$

(456,270)

 

111

%

​

For the three months ended September 30, 2026, there was a gross loss from total sales of $867,577, or 121%, compared to a gross loss of $411,307, or 35%, in the comparable period in 2025.

Products cost of sales were relatively flat as a percentage of sales for the three months ended September 30, 2026 at 62% versus 63% in the comparable 2025 period.

​

Unapplied manufacturing overhead costs, not already added into product cost of sales, increased by $277,226, or 54%, for the three months ended September 30, 2026 compared to the 2025 comparable period. As a percentage of total sales, such costs increased to 111% compared to 44% in 2025 due to lower product revenue, the reworking of older product versions into upgraded current versions, which did not result in any additional overhead absorption, and lower production levels of new product, as the Company has sufficient finished goods on hand to meet currently expected demand for current Smart Glasses models for the foreseeable future.

​

Depreciation and amortization included in cost of sales decreased by $96,864, or 54%, for the three months ended September 30, 2026 versus the comparable period in 2025. This decrease was due to certain leasehold improvements becoming fully depreciated in November 2025.

​

Research and Development.  Our research and development expenses consist primarily of compensation costs for personnel including non-cash stock-based compensation expenses, third-party services, purchase of research supplies and materials, and consulting fees related to research and development. Software development expenses to determine technical feasibility before final development and ongoing maintenance are not capitalized and are included in research and development expenses.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

% of

​

Three Months Ended

​

% of

​

Dollar

​

% Increase

​

​

  ​ ​ ​

September 30, 2026

  ​ ​ ​

Total Sales

  ​ ​ ​

September 30, 2025

  ​ ​ ​

Total Sales

  ​ ​ ​

Change

  ​ ​ ​

(Decrease)

​

Research and Development Expenses

​

$

3,090,075

 

433%

​

$

2,781,191

 

240%

​

$

308,884

 

11

%

Related Stock-based Compensation (non-cash)

​

​

227,434

 

32%

​

​

154,780

 

13%

​

​

72,654

 

47

%

Total Research and Development

​

$

3,317,509

 

464%

​

$

2,935,971

 

253%

​

$

381,538

 

13

%

​

23

Table of Contents

Total research and development expenses for the three months ended September 30, 2026 increased by $381,538, or 13%, compared to the comparable period in 2025. This increase was largely due to a $450,000 increase in external consulting expenses related to the Company’s new waveguide-based optical interconnect components being developed for CPO solutions; a $221,533 increase in cash salary and benefits related expenses due to headcount increases; partially offset by a $102,997 decrease in rent and utilities expenses; a $179,206 decrease in external product development costs; and a $76,898 decrease in recruiting and hiring expenses.

Selling and Marketing.   Selling and marketing expenses consist of trade show costs, advertising, sales samples, travel costs, sales staff compensation costs including non-cash stock-based compensation expense, consulting fees, public relations agency fees, website costs, and sales commissions paid to full-time staff and outside consultants.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

% of

​

Three Months Ended

​

% of

​

Dollar

​

% Increase

​

​

  ​ ​ ​

September 30, 2026

  ​ ​ ​

Total Sales

  ​ ​ ​

September 30, 2025

  ​ ​ ​

Total Sales

  ​ ​ ​

Change

  ​ ​ ​

(Decrease)

​

Selling and Marketing Expenses

​

$

1,518,109

​

212%

​

$

1,028,262

​

89%

​

$

489,847

​

48

%

Related Stock-based Compensation (non-cash)

​

​

122,822

​

17%

​

​

118,932

​

10%

​

​

3,890

​

3

%

Total Selling and Marketing

​

$

1,640,931

​

230%

​

$

1,147,194

​

99%

​

$

493,737

​

43

%

​

Total selling and marketing expenses for the three months ended September 30, 2026 increased by $493,737, or 43%, compared to the comparable period in 2025. This increase was largely due to a $350,000 increase in external consulting expenses related to the Company’s new waveguide-based optical interconnect components being developed for CPO solutions; and a $244,154 increase in bad debt expense, net of a $199,323 recovery of previously written-off bad debt in the prior period; partially offset by a decrease of $131,220 in cash salary and benefits related expenses.

General and Administrative.  General and administrative expenses include professional fees, investor relations (IR) and shareholder related costs, salaries and related non-cash stock-based compensation, travel costs, and office and rental costs.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

% of

​

Three Months Ended

​

% of

​

Dollar

​

% Increase

​

​

  ​ ​ ​

September 30, 2026

  ​ ​ ​

Total Sales

  ​ ​ ​

September 30, 2025

  ​ ​ ​

Total Sales

  ​ ​ ​

Change

  ​ ​ ​

(Decrease)

​

General and Administrative Expenses

​

$

1,991,440

 

279%

​

$

2,127,363

 

183%

​

$

(135,923)

 

(6)

%

Related Stock-based Compensation (non-cash)

​

​

496,459

 

69%

​

​

447,724

 

39%

​

​

48,735

 

11

%

Total General and Administrative

​

$

2,487,899

 

348%

​

$

2,575,087

 

222%

​

$

(87,188)

 

(3)

%

​

Total general and administrative expenses for the three months ended September 30, decreased by $87,188, or 3%, compared to the comparable period in 2025. The decrease was largely due to a $147,744 decrease in cash salary and benefits related expenses; a $88,353 decrease in insurance premiums; and a $60,259 decrease in IR and shareholder related expenses; partially offset by a $200,000 increase in external consulting expenses related to the Company’s new waveguide-based optical interconnect components being developed for CPO solutions.

​

Depreciation and Amortization.  Depreciation and amortization expense, not included in cost of sales or research and development expenses, for the three months ended September 30, 2026, was $163,458, compared to $424,335 in the comparable period in 2025, or a decrease of $260,877. This decrease was due to certain leasehold improvements becoming fully depreciated in November 2025.

Other Income, Net. Total other income was $91,186 for the three months ended September 30, 2026, compared to other income of $139,669 in the comparable period in 2025, a decrease of $48,483. This decrease was due to a decrease of $48,731 in investment income; and an increase of $14,000 in other taxes; partially offset by a decrease of $14,248 in foreign exchange losses.

24

Table of Contents

Provision for Income Taxes. There was no provision for income taxes in the respective three month periods ended September 30, 2026 and 2025.

Comparison of Nine months Ended September 30, 2026 and 2025

The following table compares the Company’s consolidated statements of operations data for the nine months ended September 30, 2026 and 2025:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30, 

​

​

  ​ ​ ​

​

​

  ​ ​ ​

​

​

  ​ ​ ​

Dollar

  ​ ​ ​

% Increase

 

​

​

2026

​

2025

​

Change

​

(Decrease)

 

​

​

​

​

​

​

​

​

​

​

​

​

​

Sales:

 

​

  ​

 

​

  ​

 

​

  ​

 

  ​

​

Sales of Products

​

$

2,420,816

​

$

3,265,657

​

$

(844,841)

 

(26)

%

Sales of Engineering Services

​

 

798,447

​

 

771,941

​

 

26,506

 

3

%

​

​

​

​

​

​

​

​

​

​

​

​

​

Total Sales

​

 

3,219,263

​

 

4,037,598

​

 

(818,335)

 

(20)

%

​

​

​

​

​

​

​

​

​

​

​

​

​

Cost of Sales:

​

 

  ​

​

 

  ​

​

 

  ​

 

  ​

​

Cost of Sales - Products Sold

​

 

4,196,985

​

 

4,468,385

​

 

(271,400)

 

(6)

%

Cost of Sales - Depreciation and Amortization

​

 

240,383

​

 

525,144

​

 

(284,761)

 

(54)

%

Cost of Sales - Engineering Services

​

 

672,803

​

 

481,861

​

 

190,942

 

40

%

​

​

​

​

​

​

​

​

​

​

​

​

​

Total Cost of Sales

​

 

5,110,171

​

 

5,475,390

​

 

(365,219)

 

(7)

%

​

​

​

​

​

​

​

​

​

​

​

​

​

Gross Loss

​

 

(1,890,908)

​

 

(1,437,792)

​

 

(453,116)

 

32

%

Gross Loss %

​

 

(59)

%  

 

(36)

%  

 

  ​

 

  ​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Operating Expenses:

​

 

  ​

​

 

  ​

​

 

  ​

 

  ​

​

Research and Development

​

 

9,443,739

​

 

8,112,684

​

 

1,331,055

 

16

%

Selling and Marketing

​

 

4,401,741

​

 

4,037,649

​

 

364,092

 

9

%

General and Administrative

​

 

7,304,170

​

 

9,292,659

​

 

(1,988,489)

 

(21)

%

Depreciation and Amortization

​

 

396,719

​

 

1,242,828

​

 

(846,109)

 

(68)

%

​

​

​

​

​

​

​

​

​

​

​

​

​

Loss from Operations

​

 

(23,437,277)

​

 

(24,123,612)

​

 

686,335

 

(3)

%

​

​

​

​

​

​

​

​

​

​

​

​

​

Other Income (Expense):

​

 

  ​

​

 

  ​

​

 

  ​

 

  ​

​

Investment Income

​

 

434,196

​

 

460,998

​

 

(26,802)

 

(6)

%

Other Taxes

​

 

(50,458)

​

 

22,372

​

 

(72,830)

 

(326)

%

Foreign Exchange Loss

​

 

(32,668)

​

 

(17,864)

​

 

(14,804)

 

83

%

​

​

​

​

​

​

​

​

​

​

​

​

​

Total Other Income, Net

​

 

351,070

​

 

465,506

​

 

(114,436)

 

(25)

%

​

​

​

​

​

​

​

​

​

​

​

​

​

Net Loss

​

$

(23,086,207)

​

$

(23,658,106)

​

$

571,899

 

(2)

%

​

Sales.   There was a decrease in total sales for the nine months ended September 30, 2026, compared to the same period in 2025 of $818,335, or 20%. The following table reflects the major components of our sales:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Nine Months Ended

  ​ ​ ​

% of

  ​ ​ ​

Nine Months Ended

  ​ ​ ​

% of

  ​ ​ ​

Dollar

  ​ ​ ​

% Increase

​

​

​

September 30, 2026

​

Total Sales

​

September 30, 2025

​

Total Sales

​

Change

​

(Decrease)

​

Sales of Products

​

$

2,420,816

 

75

%  

$

3,265,657

 

81

%  

$

(844,841)

 

(26)

%

Sales of Engineering Services

​

 

798,447

 

25

%  

 

771,941

 

19

%  

 

26,506

 

3

%

Total Sales

​

$

3,219,263

 

100

%  

$

4,037,598

 

100

%  

$

(818,335)

 

(20)

%

​

25

Table of Contents

Sales of products decreased by 26%, or $844,841, for the nine months ended September 30, 2026, compared to the same period in 2025. Reduced Smart Glasses revenue was the primary driver of this decrease as unit sales of our M400 product decreased, along with the unit sales of our products that were discontinued in 2025, compared to the previous year’s comparable period.

Sales of engineering services and OEM products for the nine months ended September 30, 2026, were $798,447 compared to $771,941 in the comparable 2025 period, an increase of 3%.

Cost of Sales and Gross Loss. Cost of product revenues and engineering services are comprised of materials, components, labor, warranty costs, freight costs, manufacturing overhead, software royalties, the depreciation for our tooling and manufacturing equipment, and amortization of software development costs related to the production of our products and rendering of engineering services. The following table reflects the components of our cost of sales:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

% of

​

Nine Months Ended

​

% of

​

Dollar

​

% Increase

​

​

  ​ ​ ​

September 30, 2026

  ​ ​ ​

Total Sales

  ​ ​ ​

September 30, 2025

  ​ ​ ​

Total Sales

  ​ ​ ​

Change

  ​ ​ ​

(Decrease)

​

Product Cost of Sales

​

$

1,937,689

 

61

%  

$

2,598,041

 

64

%  

$

(660,352)

 

(25)

%

Inventory Reserve for Obsolescence

​

 

287,285

 

9

%  

 

265,000

 

7

%  

 

22,285

 

8

%

Manufacturing Overhead - Unapplied

​

 

1,972,011

 

61

%  

 

1,605,344

 

40

%  

 

366,667

 

23

%

Depreciation and Amortization

​

 

240,383

 

7

%  

 

525,144

 

13

%  

 

(284,761)

 

(54)

%

Engineering Services Cost of Sales

​

 

672,803

 

21

%  

 

481,861

 

12

%  

 

190,942

 

40

%

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Total Cost of Sales

​

​

5,110,171

 

159

%  

​

5,475,390

 

136

%  

​

(365,219)

 

(7)

%

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Gross Loss

​

$

(1,890,908)

​

(59)

%

$

(1,437,792)

 

(36)

%

$

(453,116)

 

32

%

​

For the nine months ended September 30, 2026, there was a gross loss from total sales of $1,890,908, or 59%, compared to a gross loss of $1,437,792, or 36%, in the comparable period in 2025.

Products cost of sales were down slightly as a percentage of sales for the nine months ended September 30, 2026 at 60% versus 64% in the comparable 2025 period.

​

Unapplied manufacturing overhead costs, not already added into product cost of sales, increased by $366,667, or 23%, for the nine months ended September 30, 2026 compared to the 2025 comparable period. As a percentage of total sales, such costs increased to 61%, compared to 40% in 2025, due to lower product revenue, the reworking of older product versions into upgraded current versions, which did not result in any additional overhead absorption, and lower production levels of new product, as the Company has sufficient finished goods on hand to meet currently expected demand for current Smart Glasses models for the foreseeable future.

​

Depreciation and amortization included in cost of sales decreased by $284,761, or 54%, for the nine months ended September 30, 2026 versus the comparable period of 2025. This decrease was due to certain leasehold improvements becoming fully depreciated in November 2025.

​

26

Table of Contents

Research and Development.  Our research and development expenses consist primarily of compensation costs for personnel including non-cash stock-based compensation expenses, third-party services, purchase of research supplies and materials, and consulting fees related to research and development. Software development expenses to determine technical feasibility before final development and ongoing maintenance are not capitalized and are included in research and development expenses.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

% of

​

Nine Months Ended

​

% of

​

Dollar

​

% Increase

​

​

  ​ ​ ​

September 30, 2026

  ​ ​ ​

Total Sales

  ​ ​ ​

September 30, 2025

  ​ ​ ​

Total Sales

  ​ ​ ​

Change

  ​ ​ ​

(Decrease)

​

Research and Development Expenses

​

$

8,934,561

 

278

%  

$

7,420,592

 

184

%  

$

1,513,969

 

20

%

Related Stock-based Compensation (non-cash)

​

​

509,178

 

16

%  

​

692,092

 

17

%  

​

(182,914)

 

(26)

%

Total Research and Development Costs

​

$

9,443,739

 

293

%  

$

8,112,684

 

201

%  

$

1,331,055

 

16

%

​

Total research and development expenses for the nine months ended September 30, 2026 increased by $1,331,055, or 16%, compared to the comparable period in 2025. This increase was largely due to a $1,194,427 increase in cash salary and benefits related expenses due to headcount increases; a $450,000 increase in external consulting expenses related to the Company’s new waveguide-based optical interconnect components being developed for CPO solutions; a $314,769 increase in depreciation related to under-utilized new manufacturing equipment still being used primarily for R&D purposes; and a $99,584 increase in supplies expenses; partially offset by a $182,912 decrease in non-cash stock-based compensation expenses; a $125,925 decrease in rent related expenses; a $349,061 decrease in external development costs for our new products; and a $69,499 decrease in recruiting and hiring expenses.

Selling and Marketing.   Selling and marketing expenses consist of trade show costs, advertising, sales samples, travel costs, sales staff compensation costs including non-cash stock-based compensation expense, consulting fees, public relations agency fees, website costs, and sales commissions paid to full-time staff and outside consultants.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

% of

​

Nine Months Ended

​

% of

​

Dollar

​

% Increase

​

​

  ​ ​ ​

September 30, 2026

  ​ ​ ​

Total Sales

  ​ ​ ​

September 30, 2025

  ​ ​ ​

Total Sales

  ​ ​ ​

Change

  ​ ​ ​

(Decrease)

​

Selling and Marketing Expenses

​

$

4,177,937

 

130

%  

$

3,334,895

 

83

%  

$

843,042

 

25

%

Related Stock-based Compensation (non-cash)

​

​

223,804

 

7

%  

​

702,754

 

17

%  

​

(478,950)

 

(68)

%

Total Selling and Marketing

​

$

4,401,741

 

137

%  

$

4,037,649

 

100

%  

$

364,092

 

9

%

​

Total selling and marketing expenses for the nine months ended September 30, 2026 increased by $364,092, or 9%, compared to the comparable period in 2025. This was due to a $350,000 increase in external consulting expenses related to the Company’s new waveguide-based optical interconnect components being developed for CPO solutions; a $244,154 increase in bad debt expense, net of a $199,323 recovery of previously written-off bad debt in the prior period; an increase of $127,457 in cash salary and benefits related expenses; an increase of $46,966 in website development costs; a $37,181 increase in travel related expenses; partially offset by a $478,950 decrease in non-cash stock-based compensation expense.

27

Table of Contents

General and Administrative.  General and administrative expenses include professional fees, IR costs, salaries and related non-cash stock-based compensation, travel costs, and office and rental costs.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended

​

% of

​

Nine Months Ended

​

% of

​

Dollar

​

% Increase

​

​

  ​ ​ ​

September 30, 2026

  ​ ​ ​

Total Sales

  ​ ​ ​

September 30, 2025

  ​ ​ ​

Total Sales

  ​ ​ ​

Change

  ​ ​ ​

(Decrease)

​

General and Administrative Expenses

​

$

5,974,163

 

186

%  

$

6,392,430

 

158

%  

$

(418,267)

 

(7)

%

Related Stock-based Compensation (non-cash)

​

​

1,330,007

 

41

%  

​

2,900,229

 

72

%  

​

(1,570,222)

 

(54)

%

Total General and Administrative

​

$

7,304,170

 

227

%  

$

9,292,659

 

230

%  

$

(1,988,489)

 

(21)

%

​

Total general and administrative expenses for the nine months ended September 30, 2026 decreased by $1,988,489, or 21%, compared to the comparable period in 2025. The decrease was largely due to a $1,570,222 decrease in non-cash stock-based compensation expense related to our 2024 cash salary reduction program in exchange for equity, which ended on April 30, 2025, and the termination of the Company’s original LTIP, which was cancelled on June 16, 2025; a $865,900 decrease in IR and shareholder related expenses; a $115,465 decrease in legal expenses; a $93,235 decrease in insurance premiums; a $65,685 decrease in external consulting expenses; and a $45,833 decrease in rent and repair expenses; partially offset by a $311,834 increase in cash salary and benefits mostly due to our 2024 cash salary reduction program, which ended on April 30, 2025; a $200,000 increase in external consulting expenses related to the Company’s new waveguide-based optical interconnect components being developed for CPO solutions; a $99,558 increase in recruitment and hiring expenses; and a $65,462 increase in supplies expenses.

Depreciation and Amortization.  Depreciation and amortization expense, not included in cost of sales or research and development expenses, for the nine months ended September 30, 2026, was $396,719, compared to $1,242,828 in the comparable period in 2025, or a decrease of $846,109. This decrease was due to certain leasehold improvements becoming fully depreciated in November 2025.

Other Income, Net. Total other income was $351,070 for the nine months ended September 30, 2026, compared to other income of $465,506 in the comparable period in 2025, a decrease of $114,436. This decrease was due to an increase of $72,830 in other taxes; a decrease in investment income of $26,802; and an increase of $14,804 in foreign exchange losses

Provision for Income Taxes. There was no provision for income taxes in the respective nine month periods ended September 30, 2026 and 2025.

​

Liquidity and Capital Resources

Capital Resources: As of September 30, 2026, we had cash and cash equivalents of $9,192,134, a decrease of $11,958,079 from $21,150,213 as of December 31, 2025.

As of September 30, 2026, we had current assets of $14,672,764 compared to current liabilities of $4,502,303 which resulted in a positive working capital position of $10,170,461. As of December 31, 2025, we had a positive working capital position of $22,307,525. Our current liabilities are comprised principally of accounts payable, accrued expenses, and operating lease right-of-use liabilities.

​

28

Table of Contents

Summary of Cash Flows:

​

The following table summarizes our select cash flows for the nine months ended:

​

​

​

​

​

September 30, 

​

​

September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

Net Cash Provided by (Used in)

 

​

  ​

 

​

  ​

Operating Activities

​

$

(18,848,154)

​

$ (13,234,835)

Investing Activities

​

 

(3,148,741)

​

 

(2,090,434)

Financing Activities

​

 

10,038,816

​

 

19,747,292

​

During the nine months ended September 30, 2026, we used $18,848,154 of cash for operating activities, an increase of $5,613,319 from the comparable 2025 period. Net changes in working capital items were $537,295 for the nine months ended September 30, 2026, with the largest factors resulting from a $1,308,665 decrease in trade accounts and other receivables; offset by a $363,508 decrease in trade accounts payables and accrued expenses and a $348,185 increase in prepaid expenses and other assets. For the nine months ended September 30, 2025, we used a total of $13,234,835 in cash for operating activities.

During the nine months ended September 30, 2026, we used $3,148,741 of cash for investing activities, which included: $2,687,934 in manufacturing equipment and tooling, primarily for additional waveguide manufacturing equipment, and $460,807 in patent and trademark expenditures. For the nine months ended September 30, 2025, we used a total of $2,090,434 in cash for investing activities.

During the nine months ended September 30, 2026, we received $10,038,816 from financing activities, which included $10,153,739 in net proceeds from sales of common stock under our ATM program less $114,923 in Series B Preferred Stock dividend payments. For the nine months ended September 30, 2025, we received $19,747,292 from financing activities.

As of September 30, 2026, the Company does not have any current or long-term debt obligations outstanding.

​

In February 2026, the U.S. Supreme Court issued a ruling invalidating tariffs previously imposed under the International Emergency Economic Powers Act ("IEEPA"). Through March 31, 2026, the Company had paid approximately $190,000 related to IEEPA tariffs for the purchase of fixed assets and components included in the costs of sales. However, significant uncertainty remains regarding the ultimate availability, timing, and magnitude of potential refunds due to a phased administrative process, ongoing litigation, and potential appeals. Consequently, as of September 30, 2026, the Company has not recorded a receivable, asset, or gain for any unrefunded amounts because recovery of these is not considered "probable" or "reasonably estimable" under the loss recovery model of ASC 410-30 and ASC 450, with potential refunds currently treated as unrecognized gain contingencies. For the three and nine months ended September 30, 2026, the Company received refunds totaling $57,924 and $84,078, respectively, and has recognized the refunds as a reduction of cost of goods sold.

​

The Company incurred net losses of $23,086,207 for the nine months ended September 30, 2026; $32,273,128 for the year ended December 31, 2025; and $73,538,157 for the year ended December 31, 2024. The Company had net cash outflows from operations of $18,848,154 for the nine months ended September 30, 2026; $18,789,272 for the year ended December 31, 2025; and $23,739,372 for the year ended December 31, 2024. As of September 30, 2026, the Company had an accumulated deficit of $423,057,117.

​

The Company’s cash requirements going forward are primarily for funding operating losses, research and development, working capital and investments in fixed assets, patents, and trademarks. Our cash requirements related to funding operating losses depend upon numerous factors, including new product development activities, our ability to commercialize our products, our products’ timely market acceptance, selling prices and gross margins, and other factors. Historically, the Company has met its cash needs primarily through the sale of equity securities. The Company will need

29

Table of Contents

to grow its business significantly to become profitable and self-sustaining on a cash flow basis or it will be required to cut its operating costs significantly or raise new equity and/or debt capital.

​

These historical financial factors initially raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s management intends to take actions necessary to continue as a going concern, as discussed herein. Management’s plans to alleviate the conditions that raise substantial doubt include raising further capital, the implementation of operational improvements, and the curtailment of certain development programs, all of which the Company expects will preserve cash.

​

Management’s plans concerning these matters and managing our liquidity include, among other things:    

●Delaying or curtailing discretionary and non-essential operating expenses and investments in fixed assets not related to near-term product and manufacturing needs and reducing other investing activities for the remainder of our 2026 and 2027 fiscal years;
●The expected gross margin contributions once we are successful in securing volume manufacturing and sales of waveguides from our newly expanded waveguide manufacturing plant, particularly to new Smart Glasses ODM/OEM customers and future CPO AI data center customers; and
●Continued pursuit of licensing and strategic opportunities around our waveguide for imaging and CPO applications and other waveguide technologies with potential ODMs/OEMs, which may include the receipt of upfront licensing fees and on-going supply agreements.

The Company has historically raised capital through the sale of equity securities. The Company filed a Registration Statement on Form S-3 that became effective in May 2024, which included an initial sales agreement prospectus for the issuance and sale of up to $50,000,000 of our common stock from time to time under this sales agreement with an investment bank in an “at the market” offering. Subsequently, in August 2026, the Company entered into a new sales agreement with the same investment bank for the issuance of up to $100,000,000 of our common stock and all remaining unused issuance under the prior sales agreement, totaling $16,330,382, were terminated.Since May 2024, the Company has raised $32,978,341, net of broker expenses, including $10,512,048 during the nine months ended September 30, 2026, under these sales agreements.

Management will continue to utilize the available “at the market” facility noted above to satisfy obligations as they become due, as well as, monitor the capital markets on an ongoing basis and may consider raising capital under other programs if favorable market conditions develop. If the Company needs to raise capital for additional liquidity, the Company may pursue additional equity financings, further curtail expenses, or enter into one or more strategic transactions. However, management can make no assurance that the Company will be able to successfully complete any of the aforementioned pursuits on terms acceptable to the Company, or at all.

​

As a result of management’s plan above, our current amount of cash on hand, and our historical ability to raise capital, management has concluded that substantial doubt of our ability to continue as a going concern has been alleviated.

​

​

30

Table of Contents

Forward-Looking Statements

This quarterly report includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include, but are not limited to, statements concerning:

●trends in our operating expenses, including personnel costs, research and development expense, sales and marketing expense, and general and administrative expenses;
●the effect of competitors and competition in our markets;
●our wearable Smart Glasses products and their market acceptance and future potential;
●our ability to develop, timely introduce, and effectively manage the introduction of new products and services or improve our existing products and services;
●expected technological advances by us or by third parties and our ability to leverage them;
●our ability to attract and retain customers;
●our ability to accurately forecast consumer demand and adequately manage our inventory;
●our ability to deliver an adequate supply of product to meet demand;
●our ability to maintain and promote our brand and expand brand awareness;
●our ability to detect, prevent, or fix defects in our products;
●our reliance on third-party suppliers, contract manufacturers and logistics providers and our limited control over such parties;
●trends in revenue, costs of revenue, and gross margin and our possible or assumed future results of operations;
●our ability to attract and retain highly skilled employees;
●the impact of foreign currency exchange rates;
●the effect of future regulations;
●the sufficiency of our existing cash and cash equivalent balances and cash flow from operations to meet our working capital and capital expenditure needs for at least the next twelve (12) months; and
●general market, political, economic, business and public health conditions.

All statements in this quarterly report that are not historical facts are forward-looking statements. We may, in some cases, use terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions that convey uncertainty of future events or outcomes to identify forward-looking statements.

31

Table of Contents

All such forward-looking statements are subject to certain risks and uncertainties and should be evaluated in light of important risk factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These risk factors include, but are not limited to, those described in “Risk Factors” under Item 1A and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025, and other filings we make with the Securities and Exchange Commission and the following: business and economic conditions, rapid technological changes accompanied by frequent new product introductions, competitive pressures, dependence on key customers, inability to gauge order flows from customers, fluctuations in quarterly and annual results, the reliance on a limited number of third-party suppliers, limitations of our manufacturing capacity and arrangements, the protection of our proprietary technology, the dependence on key personnel, changes in critical accounting estimates, potential impairments related to investments, foreign regulations, changes in trade policy in the United States and other countries, including changes in trade agreements and the imposition of tariffs, liquidity issues, and potential material weaknesses in internal control over financial reporting. Further, during weak or uncertain economic periods, customers may delay the placement of their orders. These factors often result in a substantial portion of our revenue being derived from orders placed within a quarter and shipped in the final month of the same quarter.

We caution readers to carefully consider such factors. Many of these factors are beyond our control. In addition, any forward-looking statements represent our estimates only as of the date they are made and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, except as may be required under applicable securities laws, we specifically disclaim any obligation to do so.

​

Item 3.Quantitative and Qualitative Disclosures about Market Risk

Not Applicable

​

Item 4.Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Management, with the participation of the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has performed an evaluation of the effectiveness of our disclosure controls and procedures that are defined in Rule 13a-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this report. This evaluation included consideration of the controls, processes, and procedures that are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is properly recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our management, including our CEO and CFO, concluded that our disclosure controls and procedures were effective at September 30, 2026.

Changes in Internal Control over Financial Reporting

There have not been any changes in the Company’s internal control over financial reporting (as defined in 13a-15(f) and 15d-15(f) promulgated under the Exchange Act) that occurred during the Company’s most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

​

32

Table of Contents

Part II. OTHER INFORMATION

Item 1.Legal Proceedings

We are involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. In connection with these matters, we assess, on a regular basis, the probability and range of possible loss based upon the developments in these matters. A liability is recorded in the consolidated financial statements if the Company believes it to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review outstanding legal matters to determine the adequacy of the liabilities accrued and related disclosures in consideration of many factors, which include, but are not limited to, past history, scientific and other evidence, and the specifics and status of each matter. We may change our estimates if our assessment of the various factors changes and the amount of ultimate loss may differ from our estimates, resulting in a material effect on our business, financial condition, results of operations, and/or cash flows. With respect to these matters, based upon management’s current knowledge, the Company believes that the amount or range of any reasonably possible loss, if any, will not, either individually or in the aggregate, have a material adverse effect on the Company’s financial position, results of operations or cash flows.

​

The Company is not currently party to, nor is its property subject to, any material legal proceedings.

​

Item 1A.Risk Factors

In addition to the other information set forth in this report you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes from those risk factors, except as set forth below. The risks discussed in our 2025 Annual Report and herein could materially affect our business, financial condition and future results.

​

A substantial amount of the Company’s components and related materials are imported from abroad. The ongoing evolution of trade policies (including tariffs) could materially adversely affect the (i) costs of raw and finished components for our products, and (ii) demand for our current and future products.

​

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

Sale of Unregistered Securities - none

​

Purchase of Equity Securities: - none

​

Item 3.Defaults Upon Senior Securities

None

​

Item 4.Mine Safety Disclosures

Not Applicable

​

Item 5.Other Information

During the fiscal quarter ended September 30, 2026, no Section 16 director or officer adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act).

​

There were no “non-Rule 10b5-1 trading arrangements” (as defined in Item 408 of Regulation S-K of the Exchange Act) adopted, modified or terminated during the fiscal quarter ended September 30, 2026 by our directors and Section 16 officers.

​

​

33

Table of Contents

Item 6.Exhibits

​

Exhibit No.

  ​ ​ ​

Description

​

​

 

31.1

​

Certification of the Chief Executive Officer of the Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

​

 

31.2

​

Certification of the Chief Financial Officer of the Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

​

 

32.1

​

Certification of the Chief Executive Officer of the Registrant pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

 

​

 

32.2

​

Certification of the Chief Financial Officer of the Registrant pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

 

​

 

101

​

Inline XBRL Document set for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q.*

​

​

​

104

​

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*

​

​

​

* Filed herewith.

** Furnished herewith

​

​

.

34

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

VUZIX CORPORATION

 

 

 

Date: November 12, 2026

By:

/s/ Paul Travers

 

 

Paul Travers

 

 

President, Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

 

Date: November 12, 2026

By:

/s/ Grant Russell

 

 

Grant Russell

 

 

Executive Vice President and Chief Financial

 

 

Officer

 

 

(Principal Financial and Accounting Officer)

​

35